{
    "url": "https://www.sec.gov/Archives/edgar/data/856984/000149315224011551/form10-k.htm",
    "report_type": "10-K",
    "context": [
        {
            "id": 0,
            "context": "Background We are a medical device technology and software as a service (SaaS) company focused on enabling primary care physicians (PCP\u2019s) and other healthcare providers to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures. In some cases, the products we provide our physician clients will enable them to diagnose and treat patients with chronic diseases which they historically have referred to specialists, allowing them to increase their practice revenue. As part of our mission, we are providing PCPs and other healthcare providers with the software, training and devices necessary to allow them to treat their patients using value-based healthcare, informatics and personalized medicine. Our digital healthcare, clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, to address chronic care and preventive medicine and are reimbursable to the medical practice.",
            "type": "paragraph"
        },
        {
            "id": 1,
            "context": "Based on the success of PCPs using our Quality Health System Lab Expert System (\u201cQHSLab\u201d) digital healthcare platform combined with our AllergiEnd\u00ae product line, we intend to increase our revenues by charging physicians a monthly subscription fee for the use of QHSLab and soliciting additional PCPs to increase their revenues by using our proven revenue generating QHSLab and AllergiEnd\u00ae line of products. We also plan to introduce additional point of care diagnostics and treatments, and digital medicine programs that PCPs and other healthcare providers can use and prescribe in their practices. In all cases, providers will be paid under existing government and private insurance programs, based upon analyses conducted utilizing QHSLab and treatments provided as a result of such analyses.",
            "type": "paragraph"
        },
        {
            "id": 2,
            "context": "Industry The healthcare industry has yet to experience the improvements in outcomes, access, and cost-effectiveness that have transformed many other industries through the use of digital technologies. In an effort to address a worsening pandemic of chronic diseases associated with aging populations, technology companies are now contributing innovative solutions that enhance chronic and preventive care management through the structured capture, storage and analysis of large quantities of patient data, and remote monitoring digital applications to reduce the burden of care on healthcare systems.",
            "type": "paragraph"
        },
        {
            "id": 3,
            "context": "Digital medicine products utilizing sophisticated software to capture, store, analyze and access patient data, can be used independently or in concert with pharmaceuticals, biologics, devices, or other products to optimize patient care and health outcomes. A key component of digital medicine is the analysis of raw patient data, including physiological, psychological and environmental signals or responses to digital health risk assessments to provide the physician with result-oriented output to support their clinical decision making and better coordinate patient care and treatment.",
            "type": "paragraph"
        },
        {
            "id": 4,
            "context": "Digital Therapeutics or digital behavioral health, that is, the use of digital medicine products to assess a patient\u2019s state of health and wellbeing and monitor progress in response to recommended lifestyle changes, medication adherence and treatment regimens, is considered a treatment in its own right, and may be reimbursable depending upon a patient\u2019s health condition and diagnosis, giving health-care providers an economic incentive to engage in digital healthcare. We have added and intend to continue to add features to our QHSLab platform which allow PCPs to engage in digital medicine for which they have been and will be reimbursed.",
            "type": "paragraph"
        },
        {
            "id": 5,
            "context": "Our Operating Model\nOur mission is to enhance the quality of life of individuals and populations through physician-directed digital medicine and innovative, artificial intelligence (AI) enhanced preventive health technologies.\n\n| \u25cf | Value Based. The Company provides tools that enhance health care for patients while lowering costs to insurance providers and corporate America and allowing physicians to increase their practice revenues. |\n| \u25cf | Patient Centered. Our products streamline the relationship between physicians and their patients, providing a high quality experience for patients, and increasing the value provided to them during care. |\n| \u25cf | Time Saving. Physicians can maximize face-to-face office visits and non-face-to-face patient education while generating additional revenue through reimbursable preventative services. |\n| \u25cf | Prevention Focused. Our products are designed to promote prevention, early detection, management, and reversal of chronic diseases. |",
            "type": "table"
        },
        {
            "id": 6,
            "context": "QHSLab Expert System We have developed and are constantly upgrading our high-level, fully automated cloud-based SaaS system named the QHSLab which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database. The patients\u2019 data is analyzed by specific and proprietary algorithms, assisting the physician in making a diagnosis and prescribing a course of treatment and appropriate care coordination. We provided physicians at practices which use QHSLab with analytical tools to diagnose and treat allergies and asthma which allowed them to increase revenues by expanding the breadth of their practices. Our focus for the immediate future, is to increase the number of physicians utilizing the QHSLab platform, to charge users a monthly fee, to expand the number of diagnostic algorithms and health risk assessments incorporated into QHSLab and to add features which allow PCPs to engage in reimbursable forms of digital medicine, thereby enabling general practice physicians to increase their revenues.",
            "type": "paragraph"
        },
        {
            "id": 7,
            "context": "Our QHSLab Expert System is capable of handling large quantities of data, without compromising security, accuracy or precision. We can set parameters to accommodate prospective client physician and healthcare organizations\u2019 policies and easily deal with significant increases in user workload. Our cloud-based software and IT system scales to allow a virtually unlimited number of user sessions to be activated. By utilizing a set, well-known path built into our cloud server infrastructure our QHSLab is not only capable of scaling to a large number of users, but is also built on a globally-scalable architecture, allowing us to deliver high availability to users in just about any geographic region.",
            "type": "paragraph"
        },
        {
            "id": 8,
            "context": "The importance of identifying particular health risks and the indicators of the risks to be identified vary between different healthcare settings and sectors. Some require psychological data while others require a detailed medical history and list of medications. The data collected and analyzed by our QHSLab and the feedback provided to a physician can be tailored to provide the physician with an individualized assessment tailored to his practice.",
            "type": "paragraph"
        },
        {
            "id": 9,
            "context": "Advantages of the QHSLab Expert System QHSLab has the potential to play the same role in behavioral medicine and lifestyle interventions that pharmacological interventions play in biological medicine. It will help physicians and healthcare organizations overcome barriers preventing adoption of behavioral and therapeutic change programs for health promotion and disease prevention through easy to use applications.",
            "type": "paragraph"
        },
        {
            "id": 10,
            "context": "Through purposeful design, the QHSLab Expert System:\n\n| \u25cf | Conducts a comprehensive assessment of patient behaviors, lifestyle and disease risk; |\n| \u25cf | Integrates into existing physician and healthcare interventions; |\n| \u25cf | Collects and compiles relevant, empirical data; |\n| \u25cf | Utilizes this information for decision making; |\n| \u25cf | Accounts for individual differences yet is appropriate for whole populations; |\n| \u25cf | Provides guidelines for consistent decisions; |\n| \u25cf | Demonstrates flexibility by allowing new variables to be added; |\n| \u25cf | Requires relatively low-skilled IT involvement in assessment or patient program development; and |\n| \u25cf | Maximizes revenue by providing less costly \u2018digital\u2019 alternatives to face-to-face interactions. |",
            "type": "table"
        },
        {
            "id": 11,
            "context": "Our interventions are ideal for population-based approaches. We provide an efficient means of screening. Upon development, our interactive AI based programs will branch into in-depth assessment when a problem area is identified. QHSLab currently includes a large array of lifestyle improvement interventions that can be matched to individual user requirements.",
            "type": "paragraph"
        },
        {
            "id": 12,
            "context": "QHSLab has incorporated a wide variety of digital healthcare intervention programs including allergies and asthma, mental health, musculoskeletal health and pain, hypertension, sleep disorders, dietary assessments, weight loss and much more. Our AI driven approaches will range from patient treatment seeking interventions and motivational materials for participants in early stages of behavioral change to more detailed advice and support for participants in later stages of behavioral change. As a participant progresses (or regresses), different intervention materials will be available.",
            "type": "paragraph"
        },
        {
            "id": 13,
            "context": "Our system provides an automated recording device so that minimal amounts of progress can be detected and reinforced. Gathering data through automation provides an extensive empirical data base that can be used to both serve the participant and provide an evaluation of the effectiveness of the treatment regimen. Since health risk prevention can be very expensive in terms of the resources required to provide services to all participants, QHSLab represents a far less costly alternative.",
            "type": "paragraph"
        },
        {
            "id": 14,
            "context": "An article in the Journal of the American Medical Association (JAMA) titled \u2018Assessment of an Interactive Digital Health\u2013Based Self-management Program to Reduce Hospitalizations Among Patients With Multiple Chronic Diseases\u2019 reported on the success achieved by physicians utilizing a research system similar to QHSLab. The randomized clinical trial found that \u201camong participants who received the internet chronic disease management intervention, fewer were admitted to the hospital\u201d and \u201cdigital health interventions supporting patient self-management and self-monitoring has the potential to augment primary care among patients with multiple chronic diseases and co-morbidities.\u201d",
            "type": "paragraph"
        },
        {
            "id": 15,
            "context": "Physicians are seeking preventive and chronic care management tools for their medical decision making and patient care, including non-face to face asynchronous interventions and easy to incorporate workflow digital screenings. Today, independent physicians and their practices desire digital health relationships that meet all their needs and those of their patients, instead of having to incorporate multiple limited services from numerous digital health companies. Physicians don\u2019t have time to pick and choose among different digital health systems. QHSLab solves this problem especially for the primary care provider.",
            "type": "paragraph"
        },
        {
            "id": 16,
            "context": "AllergiEnd\u00ae The first point of contact for most allergy patients is their primary care doctor or pediatrician. There are approximately 60 million Americans affected by allergic disorders, yet there are fewer than 3,000 practicing Board Certified Allergists and approximately 2,400 Board Certified Otolaryngologists specializing in allergy or approximately 1 specialist for every 11,000 allergy sufferers. It is estimated that the number of full-time equivalent (FTE) allergists/immunologists will decline about 7 percent in coming years. Meanwhile, demand for the services these physicians provide is projected to increase by 35 percent over the foreseeable future.",
            "type": "paragraph"
        },
        {
            "id": 17,
            "context": "Only a limited number of primary care physicians have sufficient training to diagnose and treat allergy-suffering patients in their offices. The primary care provider is managing many forms of chronic diseases today that in the past were in the specialist domain, while allergies have remained the exception. We believe there is a need to equip primary care physicians, physician assistants, nurse practitioners, and nurses with the ability to diagnose and treat allergy sufferers and that this need provides a strong economic opportunity for the Company.",
            "type": "paragraph"
        },
        {
            "id": 18,
            "context": "The AllergiEnd\u00ae system empowers allergist primary care providers with means to test patients for a broad spectrum of allergens within the confines of their office, thereby enabling the physician to identify the specific cause of the patient\u2019s allergies which can lead to targeted allergen immunotherapy treatment as opposed to merely masking symptoms with various anti-histamines. The product line consists primarily of a disposable, one-time use set of FDA cleared and patented skin test applicators and a unique patented test tray for use with the test applicators.",
            "type": "paragraph"
        },
        {
            "id": 19,
            "context": "As part of our service, we provide physicians and their staff with the know-how and training in allergy screening via the QHSLab digital medicine platform, skin test confirmation of the particular allergen causing the allergy symptoms and targeted allergen immunotherapy necessary to enable the physician to desensitize positive allergic patients, thereby treating the cause of the allergies, not merely the symptoms. AllergiEnd\u00ae allergen immunotherapies are pharmacy compounded preparations provided by a contract pharmacy in response to prescriptions given by the treating physicians that slowly expose the patient to small doses of the allergen culprit, either via subcutaneous injections in the doctor\u2019s office or through convenient at home sublingual (under the tongue) oral drops. This approach is similar, if not identical, to that used by allergists the world over for many years. This builds the body\u2019s immune system to the allergens, thereby overcoming the patient\u2019s excessive reaction to allergens that were previously causing allergy symptoms. Allergen Immunotherapy practiced safety is the only known method of treatment that leads to prolonged tolerance to the allergens causing the patient\u2019s allergic chronic disease. In addition to enhancing the level of care doctors can provide their patients; the screening, testing and allergen immunotherapy are reimbursable under established CPT codes enhancing the physician\u2019s practice and, in many instances, also providing a new cash pay alternative for physicians and their patients.",
            "type": "paragraph"
        },
        {
            "id": 20,
            "context": "Q-Scale Psychological Emotional Wellbeing\nIt has been suggested that nearly 75% of all medical office visits (to all types of healthcare providers) are related to stress, anxiety and depression.\n\nThe Q-Scale is a digital health 10-item questionnaire designed to measure psycho-emotional factors in patients at risk of mental health issues.\n\nThis assessment provides immediate feedback to patients while allowing for substantial reimbursements for physicians.\n For our physician customers, the product is time-saving, maximizing face-to-face office visits while generating additional revenue through reimbursement codes accepted by commercial payors, Medicare and Medicaid. From a patient perspective, Q-Scale promotes early detection and treatment of conditions potentially related to stress, anxiety, or depression, and increases the value provided to patients during their care.",
            "type": "paragraph"
        },
        {
            "id": 21,
            "context": "Industry trends also reinforce the growing need for new and time-sensitive approaches for the treatment of mental health-related issues. According to the Centers for Disease Control and Prevention, one in five Americans will experience a mental illness in a given year. Also, one in 25 Americans will be impacted by a severe mental illness, such as schizophrenia, bipolar disorder, or major depression. In addition, a recent study published by KFF, a non-profit organization focused on health-care issues, indicated that the COVID-19 pandemic and resulting economic recession have negatively affected many people\u2019s mental health with up to 40% of people reporting anxiety and depressive-related symptoms.",
            "type": "paragraph"
        },
        {
            "id": 22,
            "context": "Key aspects of the Q-Scale product include:\n\u25cf Utilizes QHSLab\u2019s cloud-based software and technology system that scales to allow a virtually unlimited number of user sessions to be activated and integrates into existing physician and healthcare interventions while collecting and compiling relevant, empirical data. \u25cf Measures a patient\u2019s responses, identifying early \u201cwarning\u201d signs using questions regarding their sleep, stress, anxiety, worry, pain and overall life satisfaction. Patients determined to have high mental health risks are identified for further screening during the same assessment. Items in the Q-Scale have been deliberately written to emphasize normal psychological functioning in generally healthy patients, therefore it is a total population screening tool.",
            "type": "paragraph"
        },
        {
            "id": 23,
            "context": "\u25cf If responses to the Q-Scale indicate potential mental health issues, patients are directed to the PHQ-9, GAD-7 and Kessler 6, a global measure of distress drawing from depressive and anxiety related symptomology. The treating physician is then alerted to the need for more focused evaluation during their encounter with the patient.",
            "type": "paragraph"
        },
        {
            "id": 24,
            "context": "\u25cf Patients receive a post-assessment digital \u2018feedback\u2019 report and self-management strategies useful in addressing any items identified during the assessment.\n\nExecuting on our Growth Strategy\n\n| Growing Recuring Revenue Base | \u25cf | Increasing the number of medical practitioners utilizing our point-of-care and digital medicine services, growing our revenue per client metric. |\n| \u25cf | Future distribution channels include Management Service Organization (MSO) partnerships, Independent Physician Associations (IPA\u2019s), and complementary digital health networks. |\n| Expanding Product Portfolio | \u25cf | Additional point-of-care diagnostic, digital medicine, and treatments that PCPs can use, prescribe, and be reimbursed for under existing government and private insurance programs. |\n| Increasing Industry Visibility | \u25cf | Increasing the number of company/university-sponsored medical conferences partnering with various Universities to introduce and educate members of the medical community about the technology and revenue opportunities available. |",
            "type": "table"
        },
        {
            "id": 25,
            "context": "Competition The market for future point of care and software as a service solution is highly competitive and characterized by rapid change. The success of our solutions will be contingent upon our ability to provide superior solutions and a strong value proposition for potential customers and their patients. Many existing competitors are well-established and enjoy greater resources or other strategic advantages. It is likely that there will be new entrants into our market, some of which may become significant competitors. With the introduction of new technologies and market entrants, we expect the competitive environment to be and remain intense. We currently face competition from a range of companies, including Phresia, Qure4U, Linus Health, Chadis, Yosi Health, Health Note, DarioHealth Corp and Noom, Inc., some of which market direct to the consumer, bypassing physicians.",
            "type": "paragraph"
        },
        {
            "id": 26,
            "context": "Our main competitors fall into the following categories:\n\u25cf private and public companies that offer specific chronic disease products and services, such as solutions for allergies and asthma, diabetes, hypertension, and certain addictions or behavioral health conditions;\n\u25cf large enterprises focused on the healthcare industry, including initiatives and partnerships launched by companies which may offer or develop products or services with features or benefits that overlap with our proposed future solutions; and\n\u25cf digital health, electronic records, device manufacturers that facilitate the collection of data but offer limited interpretation, feedback or guidance.\nMany of our current competitors enjoy greater resources, recognition, deeper customer relationships, larger existing customer bases, and more mature intellectual property portfolios than we do currently.\nIntellectual Property Although certain of our current software applications and pioneering methods, as well as those developed in the future, will be eligible for patent and trademark protection, we believe that the costs of maintaining and enforcing such intellectual property rights may not afford us a competitive advantage and for the immediate future we intend to rely primarily on maintaining the secrecy of our proprietary information.",
            "type": "paragraph"
        },
        {
            "id": 27,
            "context": "Government Regulation The healthcare industry is heavily regulated and closely scrutinized by federal, state and local governments. Comprehensive statutes and regulations govern the manner in which we and the PCPs which use our products provide and bill for services and collect reimbursement from governmental programs and private payors, our contractual relationships with vendors and clients, our marketing activities and other aspects of our operations. Of particular importance are:",
            "type": "paragraph"
        },
        {
            "id": 28,
            "context": "| \u25cf | the federal physician self-referral law, commonly referred to as the Stark Law; |\n| \u25cf | the federal Anti-Kickback Act; |\n| \u25cf | the criminal healthcare fraud provisions of HIPAA; |\n| \u25cf | the federal False Claims Act; |\n| \u25cf | reassignment of payment rules that prohibit certain types of billing and collection by companies which do business with PCPs; |\n| \u25cf | similar state law provisions pertaining to anti-kickback, self-referral and false claims issues; |\n| \u25cf | state laws that prohibit general business corporations, such as us, from practicing medicine; and |\n| \u25cf | laws that regulate debt collection practices as applied to our debt collection practices. |",
            "type": "table"
        },
        {
            "id": 29,
            "context": "Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Dealing with investigations can be time- and resource-consuming and can divert management\u2019s attention from our business.",
            "type": "paragraph"
        },
        {
            "id": 30,
            "context": "The FDA issued a Finalized Guidance on medical mobile applications (\u201cApps\u201d). The FDA determined that certain Apps may meet the definition of a medical device because they provide the user with certain biologic information. The Guidance contains an appendix that provides examples of mobile apps that may meet the definition of a medical device but for which the FDA intends to exercise enforcement discretion. These mobile apps may be intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease. Even though these mobile apps may meet the definition of a medical device, the FDA intends to exercise enforcement discretion for these mobile apps because they pose lower risk to the public. Based on our understanding of the Guidance, although there can be no guarantee, we believe our QHSLab services will eventually be subject to regulatory requirements because such services seem to fall within the statutory examples of medical devices with respect to which the FDA intends to monitor compliance with applicable regulations. Although many of the Apps described in the Guidance have been in use for an extended period of time, the impact they have had on the need for patient visits to a physician and thus, on the use of our products, has not been determined.",
            "type": "paragraph"
        },
        {
            "id": 31,
            "context": "Employees As of March 27, 2024, we had four employees devoting full-time services to the Company, all of whom were engaged in direct sales and operations. In addition, we engage independent entities and consultants that provide programming services, Quality Management System development, Marketing and Medical Consulting & Advisory services. We believe that our relationships with our employees and consultants are good.",
            "type": "paragraph"
        },
        {
            "id": 32,
            "context": "You should carefully consider each of the following risks and all of the other information set forth in this annual report. The following risks relate principally to our business and our common stock. These risks and uncertainties are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. If any of the risks and uncertainties develop into actual events, this could have a material adverse effect on our business, financial condition or results of operations. In that case, the trading price of our common stock could decline. Please also see the section \u201cGovernment Regulation\u201d above.",
            "type": "paragraph"
        },
        {
            "id": 33,
            "context": "Risks Related to Our Business\nWe incurred net losses in 2023 and 2022 and may not be able to continue to operate as a going concern. We suffered net losses of $468,362 and $996,001 for the years ended December 31, 2023 and 2022, respectively. We also had negative cash flows from operations for the years ended December 31, 2023 and 2022. During the years ended December 31, 2023 and 2022, to support our operations we received loans in the aggregate amount of $1,031,736. The report of our independent registered public accountants on our consolidated financial statements for the year ended December 31, 2023 states that these factors raise uncertainty about our ability to continue as a going concern.",
            "type": "paragraph"
        },
        {
            "id": 34,
            "context": "Unless we are able to generate positive cash flows from operations, we will continue to depend upon further issuances of debt, equity or other financings to fund ongoing operations. We may continue to incur additional operating losses and we cannot assure you that we will continue as a going concern.",
            "type": "paragraph"
        },
        {
            "id": 35,
            "context": "We are highly leveraged and we may need additional financing. We have funded our operating losses through borrowings, and merchant cash advances. As of the date of this annual report we have notes and loans outstanding in the aggregate amount, inclusive of accrued interest, of $1,954,595. Our Original Issue Discount Secured Convertible Promissory Note in the principal amount of $440,000 matured on July 19, 2023 and our Original Issue Discount Secured Convertible Promissory Note in the principal amount of $695,500 matured on August 10, 2022. On March 27, 2024, the Company received the most recent notice from the manager of the Mercer Fund of its agreement to forebear from the exercise of any rights it might have as a result of any defaults under this Note and the related documents between us and the Mercer Fund, provided that the Mercer Fund reserved all of its rights under such agreements. The Note continues to accrue interest at 5%.",
            "type": "paragraph"
        },
        {
            "id": 36,
            "context": "If we are not able to pay or refinance the outstanding principal and accrued interest on these notes when due, our operations may be materially and adversely affected. We may need to offer the holders of our debt increases in the rates of interest they receive or otherwise compensate them through payments of cash or issuances of our equity securities or reductions in the price at which they can convert their convertible securities. Future financings or re-financings may involve the issuance of additional debt, equity and securities convertible into or exercisable for our equity securities. If we are unable to consummate such financings or re-financings, the trading price of our common stock could be adversely affected and the terms of such financings may adversely affect the interests of our existing stockholders. Any failure to obtain additional working capital when required would have a material adverse affect on our business and financial condition and may result in a decline in the price of our common stock. If we are not able to fund ongoing losses through funds provided by third parties or our principal shareholder, we may become insolvent.",
            "type": "paragraph"
        },
        {
            "id": 37,
            "context": "Servicing our debt requires a significant amount of cash. Our ability to make payments on and to refinance our debt, to fund planned capital expenditures and to maintain sufficient working capital depends on our ability to generate cash in the future. This is subject to numerous factors beyond our control, including our ability to expand our physician client base. We cannot assure you that our business will generate sufficient cash flow from operations in an amount sufficient to enable us to service our debt or to fund our other liquidity needs. If our cash flow and capital resources are insufficient to allow us to make scheduled payments on our debt, we will need to seek additional capital or restructure or refinance all or a portion of our debt on or before the maturity thereof, any of which could have a material adverse effect on our business, financial condition or results of operations. We cannot assure you that we will be able to refinance any of our debt on commercially reasonable terms or at all. If we are unable to generate sufficient cash flow to repay or refinance our debt on favorable terms, it could significantly adversely affect our financial condition and the value of our outstanding debt and common stock. Our ability to restructure or refinance our debt will depend on the condition of the capital markets and our financial condition. Any refinancing of our debt could be at higher interest rates and could require us to issue to the holders additional shares of our common stock and may require us to comply with more onerous covenants, which could further restrict our business operations. There can be no assurance that we will be able to obtain any financing when needed.",
            "type": "paragraph"
        },
        {
            "id": 38,
            "context": "Our leverage may adversely affect our ability to finance future operations and capital needs and may limit our ability to pursue business opportunities.\nWe are an early stage company with a short operating history and a relatively new business model in an emerging and rapidly evolving market, which makes it difficult to evaluate our future prospects. We are an early stage entity subject to all of the risks inherent in a young business enterprise, such as, lack of market recognition and limited banking and financial relationships. We have little operating history to aid in our assessing future prospects. We will encounter risks and difficulties as an early stage company in a new and rapidly evolving market. We may not be able to successfully address these risks and difficulties, which could materially harm our business and operating results.",
            "type": "paragraph"
        },
        {
            "id": 39,
            "context": "We are not generating sufficient revenues to achieve our business plan. We first generated revenues in the fourth quarter of 2020. There is no assurance that we will generate sufficient revenues to become cash flow positive or ever be profitable. If planned operating levels are changed, higher operating costs encountered, more time needed to implement our plan, or less funding is received, more funds than currently anticipated may be required. If additional capital is not available when required, if at all, or is not available on acceptable terms we may be forced to modify or abandon our business plans.",
            "type": "paragraph"
        },
        {
            "id": 40,
            "context": "We have identified material weaknesses in our internal controls, and we cannot provide assurances that these weaknesses will be effectively remediated or that additional material weaknesses will not occur in the future. If our internal control over financial reporting or our disclosure controls and procedures are not effective, we may not be able to accurately report our financial results, prevent fraud, or file our periodic reports in a timely manner, which may cause investors to lose confidence in us and lead to a decline in our stock price. We cannot remedy the deficiencies in our internal controls until we increase the number of officers in our Company.",
            "type": "paragraph"
        },
        {
            "id": 41,
            "context": "Our management is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined in Rule 13a-15(f) under the Exchange Act. We have identified material weaknesses in our internal controls with respect to our segregation of duties, which cannot be rectified until we have additional officers, and our limited resources and our insufficient controls over review of accounting for certain complex transactions therefore our disclosure controls and procedures are not effective in providing material information required to be included in our periodic SEC filings on a timely basis and to ensure that information required to be disclosed in our periodic SEC filings is accumulated and communicated to our management to allow timely decisions regarding required disclosure about our internal control over financial reporting. Some of the material weaknesses in our internal controls are due to our limited management staff. Due to limited staffing, we are not always able to detect errors or omissions in financial reporting and cannot eliminate weaknesses due to our inability to segregate duties. If we fail to comply with the rules under Sarbanes-Oxley related to disclosure controls and procedures in the future or continue to have material weaknesses and other deficiencies in our internal control and accounting procedures and disclosure controls and procedures, our stock price could decline significantly and raising capital could be more difficult. If additional material weaknesses or significant deficiencies are discovered or if we otherwise fail to address the adequacy of our internal control and disclosure controls and procedures our business may be harmed. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important to helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our securities could drop significantly.",
            "type": "paragraph"
        },
        {
            "id": 42,
            "context": "All of our revenues have been generated from a limited number of product lines. To date, all of our revenue has been derived from a limited number of product lines. If we fail to develop or acquire additional products or services from which we can generate revenues, we may not achieve sustained positive cash flow or generate profits. As a result, we will be severely constrained in our ability to fund our operations and achieve our business plan.",
            "type": "paragraph"
        },
        {
            "id": 43,
            "context": "We are dependent upon third parties for our products. We depend upon third parties to supply us with all of the products included in the \u201cAllergiEnd\u201d line of products from which we currently derive most of our revenues. If these parties were unable or unwilling to continue to supply our needs, we might not be able to find an alternative source of supply which would materially adversely impact our business, financial condition and operating results.",
            "type": "paragraph"
        },
        {
            "id": 44,
            "context": "We have engaged in limited product development activities and our product development efforts may not result in commercial products. Although our QHSLab has been provided to physicians and enabled them to generate revenues, we have only recently begun to charge physicians for this product under various software as a service, subscription and license based revenue models. We intend to develop additional features to be added to QHSLab to provide PCPs with additional sources of revenue. There is no assurance that any of the new features we develop will gain market acceptance. We cannot guarantee we will be able to produce commercially successful products. Further, our eventual operating results could be susceptible to varying interpretations by potential customers, or scientists, medical personnel, regulatory personnel, statisticians and others, which may delay, limit or prevent executing our proposed business plan.",
            "type": "paragraph"
        },
        {
            "id": 45,
            "context": "Our business model is unproven with no assurance of any revenues or operating profits. Our current business model is unproven and the profit potential, if any, is unknown. We are subject to all the risks inherent in a new business model. There can be no assurance that our business model will prove successful or that we will achieve significant revenue or profitability.",
            "type": "paragraph"
        },
        {
            "id": 46,
            "context": "If we fail to raise additional capital, our ability to implement our business plan and strategy could be compromised. We have limited capital resources and operations. To date, our operations primarily have been funded from capital contributions and loans from our principal shareholder and more recently, third party loans. We may not be able to obtain additional financing on terms acceptable to us, or at all. Even if we obtain financing for our near-term operations and product development, we may require additional capital beyond the near term. If we are unable to raise capital when needed, our business, financial condition and results of operations would be materially adversely affected, and we could be forced to reduce or discontinue our operations.",
            "type": "paragraph"
        },
        {
            "id": 47,
            "context": "If we issue additional shares of common stock, it would reduce our stockholders\u2019 percent of ownership and may dilute our share value. Our Certificate of Incorporation authorizes the issuance of 900 million shares of common stock. As at March 27, 2024 we have outstanding 10,215,508 shares of common stock, without giving effect to shares issuable upon conversion or exercise of convertible notes, preferred stock, options and warrants currently outstanding. The future issuance of common stock or securities exercisable for or convertible into common stock to raise capital may result in substantial dilution in the percentage of our common stock held by our then existing stockholders. We may value any common stock issued in the future on an arbitrary basis. The issuance of common stock upon the conversion or exercise of outstanding notes and warrants, for future services or acquisitions or other corporate actions may have the effect of diluting the value of the shares held by our then existing stockholders and might have an adverse effect on any trading market for our common stock.",
            "type": "paragraph"
        },
        {
            "id": 48,
            "context": "Dependence on Key Existing and Future Personnel. Our success depends, to a large degree, upon the efforts and abilities of Troy Grogan, our sole officer, and key consultants. The loss of the services of one or more of our key providers could have a material adverse effect on our operations. In addition, as our business model is implemented, we will need to recruit and retain additional management, financial personnel, key employees and consulting service providers in virtually all phases of our operations. Key employees and consultants will require a strong background in our industry. We cannot assure that we will be able to successfully attract and retain key personnel.",
            "type": "paragraph"
        },
        {
            "id": 49,
            "context": "Our sole officer and director is engaged in other business activities and has a conflict in determining how much time to devote to our affairs. His failure to devote sufficient time to our business cloud have a negative impact on our operations. Our sole executive officer and director is not required to, and will not, commit his full time to our affairs, which results in a conflict of interest in allocating his time between our operations and the other businesses in which he is engaged. Our sole executive officer and director is engaged in several other business endeavors and is not obligated to contribute any specific number of hours to our affairs. His failure to devote time to our business could have an adverse impact on our business, results of operations and financial condition.",
            "type": "paragraph"
        },
        {
            "id": 50,
            "context": "We operate in a highly competitive industry. We encounter competition from local, regional or national entities, some of which have superior resources or other competitive advantages. Intense competition may adversely affect our business, financial condition or results of operations. Our competitors may be larger and more highly capitalized, with greater name recognition. We will compete with such companies on brand name, quality of services, level of expertise, advertising, product and service innovation and differentiation of product and services. As a result, our ability to secure significant market share may be impeded.",
            "type": "paragraph"
        },
        {
            "id": 51,
            "context": "We face substantial competition, and others may discover, develop, acquire or commercialize competitive products before or more successfully than we do. We operate in a highly competitive environment. Our products compete with other products or treatments for diseases for which our products may be indicated. Other healthcare companies have greater clinical, research, regulatory and marketing resources than us. In addition, some of our competitors may have technical or competitive advantages for the development of technologies and processes. These resources may make it difficult for us to compete with them to successfully discover, develop and market new products.",
            "type": "paragraph"
        },
        {
            "id": 52,
            "context": "The growth of our business relies, in part, on the growth and success of our clients. The utility of our products to our clients will be determined by their ability to incorporate them into their health care regimen and the acceptance of our products by their patients. The ability of our clients to incorporate our products into their practices is outside of our control. In addition, if the number of patients of one or more of our clients using our products were to be reduced, such decrease would lead to a decrease in our revenue.",
            "type": "paragraph"
        },
        {
            "id": 53,
            "context": "We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, financial condition, and results of operations.",
            "type": "paragraph"
        },
        {
            "id": 54,
            "context": "The healthcare industry is heavily regulated and closely scrutinized by federal, state and local governments. Comprehensive statutes and regulations govern the products we offer and the manner in which we provide and bill for services and collect reimbursement from governmental programs and private payors, our contractual relationships with our providers, vendors and clients, our marketing activities and other aspects of our operations. Of particular importance are:",
            "type": "paragraph"
        },
        {
            "id": 55,
            "context": "| \u25cf | the federal physician self-referral law, commonly referred to as the Stark Law; |\n| \u25cf | the federal Anti-Kickback Act; |\n| \u25cf | the criminal healthcare fraud provisions of HIPAA; |\n| \u25cf | the federal False Claims Act; |\n| \u25cf | reassignment of payment rules that prohibit certain types of billing and collection; |\n| \u25cf | similar state law provisions pertaining to anti-kickback, self-referral and false claims issues; |\n| \u25cf | state laws that prohibit general business corporations, such as us, from practicing medicine; and |\n| \u25cf | laws that regulate debt collection practices as applied to our debt collection practices. |",
            "type": "table"
        },
        {
            "id": 56,
            "context": "Some of our business activities could be subject to challenge under one or more of such laws. Achieving and sustaining compliance with these laws may prove costly. Failure to comply with these laws and other laws can result in civil and criminal penalties such as fines, damages, overpayment recoupment, loss of enrollment status and exclusion from the Medicare and Medicaid programs. The risk of our being found in violation of these laws and regulations is increased by the fact that many of their provisions are open to a variety of interpretations. Our failure to accurately anticipate the application of these laws and regulations to our business or any other failure to comply with regulatory requirements could create liability for us and negatively affect our business. Any action against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management\u2019s attention from the operation of our business and result in adverse publicity. Dealing with investigations can be time- and resource-consuming. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. In addition, because of the potential for large monetary exposure under the federal False Claims Act, which provides for treble damages and mandatory minimum penalties of $5,500 to $11,000 per false claim or statement, healthcare providers often resolve allegations without admissions of liability for significant and material amounts to avoid the uncertainty of treble damages that may be awarded in litigation proceedings. Such settlements often contain additional compliance and reporting requirements as part of a consent decree, settlement agreement or corporate integrity agreement. It is expected that the government will continue to devote substantial resources to investigating healthcare providers\u2019 compliance with the healthcare reimbursement rules and fraud and abuse laws. The laws, regulations and standards governing the provision of healthcare services may change significantly in the future.",
            "type": "paragraph"
        },
        {
            "id": 57,
            "context": "Developments in the healthcare industry could adversely affect our business. Developments in the healthcare industry and evolving government policy could adversely affect healthcare spending and reimbursement for healthcare services. We expect that we will be particularly dependent on primary care physicians and possibly others in the healthcare industry who are dependent upon revenues derived from federal healthcare programs.",
            "type": "paragraph"
        },
        {
            "id": 58,
            "context": "General reductions in expenditures by healthcare industry participants could result from, among other things:\n\n| \u25cf government or private initiatives that affect the manner in which healthcare providers interact with patients, payers or other healthcare industry participants, including changes in pricing or means of delivery of healthcare products and services; |\n| \u25cf consolidation of healthcare industry participants; |\n| \u25cf reductions in governmental funding for healthcare; |\n| \u25cfadverse changes in business or economic conditions affecting healthcare payers or providers, pharmaceutical, biotechnology or medical device companies or other healthcare industry participants; and |\n| \u25cf restructuring of the healthcare industry and possible elimination of private insurers. |",
            "type": "table"
        },
        {
            "id": 59,
            "context": "Even if general expenditures by industry participants remain the same or increase, developments in the healthcare industry may result in reduced spending for the products or services we provide. The use of our products and services could be affected by changes in health insurance plans resulting in a decrease in the willingness of PCPs to purchase our products.",
            "type": "paragraph"
        },
        {
            "id": 60,
            "context": "The timing and impact of developments in the healthcare industry are difficult to predict. We cannot assure you that the markets for any products we may seek to distribute and services we provide will be sustained. Our use and disclosure of personally identifiable information, including health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our client base, membership base and revenue.",
            "type": "paragraph"
        },
        {
            "id": 61,
            "context": "Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability and integrity of personally identifiable information (PII), including protected health information (PHI). HIPAA establishes a set of basic national privacy and security standards for the protection of PHI, by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the businesses with which covered entities contract for services, which includes us. HIPAA requires companies like us to develop and maintain policies and procedures with respect to PHI, including the adoption of administrative, physical and technical safeguards to protect such information. HIPAA imposes mandatory penalties for certain violations which can be significant. HIPAA mandates that the Secretary of Health and Human Services, or HHS conduct periodic compliance audits of HIPAA covered entities or business associates. It also tasks HHS with establishing a methodology whereby individuals who were the victims of breaches of unsecured PHI may receive a percentage of the Civil Monetary Penalty fine paid by the violator. HIPAA further requires that patients and, in some instances, HHS be notified of any unauthorized acquisition, access, use or disclosure of their unsecured PHI that compromises the privacy or security of such information, with certain exceptions. Numerous other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PHI. These laws in many cases are more restrictive than, and may not be preempted by, HIPAA, creating complex compliance issues for us and our clients potentially exposing us to additional expense, adverse publicity and liability. If we do not comply with existing or new laws and regulations related to PHI, we could be subject to criminal or civil sanctions. Because of the extreme sensitivity of the PHI we store and transmit, the security features of our technology platform are very important. If our security measures, some of which are managed by third parties, are breached or fail, unauthorized persons may obtain access to sensitive client and patient data, including HIPAA-regulated PHI. As a result, our reputation could be severely damaged, adversely affecting client and patient confidence. Clients may curtail their use of or stop using our services or our client base could decrease, which would cause our business to suffer. In addition, we could face litigation, damages for contract breach, penalties and regulatory actions for violation of HIPAA and other applicable laws or regulations and significant costs for remediation, notification to individuals and for measures to prevent future occurrences. Any security breach could also result in increased costs associated with liability for stolen assets or information, repairing system damage that caused by such breaches, incentives offered to clients or other business partners in an effort to maintain business relationships after a breach and implementing measures to prevent future occurrences, including organizational changes, deploying additional personnel and protection technologies, training employees and engaging third-party experts and consultants. While we maintain insurance covering certain security and privacy damages and claim expenses, we may not carry insurance or maintain coverage sufficient to compensate for all liability and in any event, insurance coverage would not address the reputational damage that could result from a security incident. We outsource important aspects of the storage and transmission of client and patient information, and thus rely on third parties to manage functions that have material cyber-security risks. We attempt to address these risks by requiring outsourcing subcontractors who handle client and patient information to sign business associate agreements contractually requiring those subcontractors to adequately safeguard personal health data to the same extent that applies to us and in some cases by requiring such outsourcing subcontractors to undergo third-party security examinations. However, we cannot assure you that these contractual measures and other safeguards will adequately protect us from the risks associated with the storage and transmission of client and patient proprietary and protected health information.",
            "type": "paragraph"
        },
        {
            "id": 62,
            "context": "The security of our platform, networks or computer systems may be breached, and any unauthorized access to our customer data will have an adverse effect on our business and reputation. The use of our products will involve the storage, transmission and processing of our clients\u2019 and their patients\u2019 private data. Individuals or entities may attempt to penetrate our network or platform security, or that of our third-party hosting and storage providers, and could gain access to our clients\u2019 and their patients\u2019 private data, which could result in the destruction, disclosure or misappropriation of proprietary or confidential information of our clients\u2019 and their patients\u2019 or their customers, employees and business partners. If any of our clients\u2019 private data is leaked, obtained by others or destroyed without authorization, it could harm our reputation, we could be exposed to civil and criminal liability, and we may lose our ability to access private data, which will adversely affect the quality and performance of our platform. In addition, our platform may be subject to computer malware, viruses and computer hacking, fraudulent use attempts and phishing attacks, all of which have become more prevalent. Any failure to maintain the performance, reliability, security and availability of our products or services and technical infrastructure to the satisfaction of our clients may harm our reputation and our ability to retain existing customers and attract new users. While we will implement procedures and safeguards that are designed to prevent security breaches and cyber-attacks, they may not be able to protect against all attempts to breach our systems, and we may not become aware in a timely manner of any such security breach. Unauthorized access to or security breaches of our platform, network or computer systems, or those of our technology service providers, could result in the loss of business, reputational damage, regulatory investigations and orders, litigation, indemnity obligations, damages for contract breach, civil and criminal penalties for violation of applicable laws, regulations or contractual obligations, and significant costs, fees and other monetary payments for remediation. If customers believe that our platform does not provide adequate security for the storage of sensitive information or its transmission over the Internet, our business will be harmed. Customers\u2019 concerns about security or privacy may deter them from using our platform for activities that involve personal or other sensitive information.",
            "type": "paragraph"
        },
        {
            "id": 63,
            "context": "Because we rely on the internet to interact with our clients, we are subject to an extensive and highly-evolving regulatory landscape and any adverse changes to, or our failure to comply with, any laws and regulations could adversely affect our brand, reputation, business, operating results, and financial condition.",
            "type": "paragraph"
        },
        {
            "id": 64,
            "context": "Our business and the businesses of our customers conducted using our platform and technology, are subject to extensive laws, rules, regulations, policies, orders, determinations, directives, treaties, and legal and regulatory interpretations and guidance directed to those who conduct business over the internet, including those governing privacy, data governance, data protection, cybersecurity, fraud detection, payment services, consumer protection and tax. Many of these legal and regulatory regimes were adopted prior to the advent of the internet, mobile technologies, digital assets, and related technologies. As a result, they are subject to significant uncertainty, and vary widely across U.S. federal, state, and local jurisdictions. These legal and regulatory regimes, including the laws, rules, and regulations thereunder, evolve frequently and may be modified, interpreted, and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another. To the extent we have not complied with such laws, rules, and regulations, we could be subject to significant fines, revocation of licenses, limitations on our products and services, reputational harm, and other regulatory consequences, each of which may be significant and could adversely affect our business, operating results, and financial condition.",
            "type": "paragraph"
        },
        {
            "id": 65,
            "context": "In addition to existing laws and regulations, various governmental and regulatory bodies, including legislative and executive bodies, in the United States may adopt new laws and regulations, or new interpretations of existing laws and regulations may be issued by such bodies or the judiciary, which may change how we operate our business, how our products and services and those of our customers are regulated, and what products or services we and our competitors can offer, requiring changes to our compliance and risk mitigation measures",
            "type": "paragraph"
        },
        {
            "id": 66,
            "context": "To the extent we use \u201copen source\u201d software, our use could adversely affect our ability to offer our services and subject us to possible litigation. We may use open source software in connection with our products and services. Companies that incorporate open source software into their products have, from time to time, faced claims challenging the use of open source software and/or compliance with open source license terms. As a result, we could be subject to suits by parties claiming ownership of what we believe to be open source software or claiming noncompliance with open source licensing terms. Some open source software licenses require users who distribute software containing open source software to publicly disclose all or part of the source code to such software and/or make available any derivative works of the open source code, which could include valuable proprietary code of the user, on unfavorable terms or at no cost. While we monitor the use of open source software and try to ensure that none is used in a manner that would require us to disclose our proprietary source code or that would otherwise breach the terms of an open source agreement, such use could inadvertently occur, in part because open source license terms are often ambiguous. Any requirement to disclose our proprietary source code or pay damages for breach of contract could have a material adverse effect on our business, financial condition and results of operations and could help our competitors develop products and services that are similar to or better than ours.",
            "type": "paragraph"
        },
        {
            "id": 67,
            "context": "Assertions by third parties of infringement or other violations by us of their intellectual property rights could result in significant costs and harm our business and operating results. Our success depends upon our ability to refrain from infringing upon the intellectual property rights of others. Some companies, including some of our competitors, own large numbers of patents, copyrights and trademarks, which they may use to assert claims against us. As we grow and enter new markets, we will face a growing number of competitors. As the number of competitors in our industry grows and the functionality of products in different industry segments overlaps, we expect that software and other solutions in our industry may be subject to such claims by third parties. Third parties may in the future assert claims of infringement, misappropriation or other violations of intellectual property rights against us. We cannot assure you that infringement claims will not be asserted against us in the future, or that, if asserted, any infringement claim will be successfully defended. A successful claim against us could require that we pay substantial damages or ongoing royalty payments, prevent us from offering our services, or require that we comply with other unfavorable terms. We may also be obligated to indemnify our customers or business partners or pay substantial settlement costs, including royalty payments, in connection with any such claim or litigation and to obtain licenses, modify applications or refund fees, which could be costly. Even if we were to prevail in such a dispute, any litigation regarding our intellectual property could be costly and time-consuming and divert the attention of our management and key personnel from our business operations.",
            "type": "paragraph"
        },
        {
            "id": 68,
            "context": "Natural disasters, unusually adverse weather conditions, pandemic outbreaks, terrorist acts, conflicts between nations and the response of governments to such occurrences, could impair our ability to purchase, receive or replenish inventory or raw materials or could cause US agencies and insurance companies to modify reimbursement policies, which could result in lost sales, reduced revenues and otherwise adversely affect our financial performance.",
            "type": "paragraph"
        },
        {
            "id": 69,
            "context": "The occurrence of one or more natural disasters, unusually adverse weather conditions, pandemic outbreaks, such as the recent outbreak of the coronavirus, or COVID-19, terrorist acts, conflicts between nations or rogue groups, and the response of governments and US agencies to such occurrences, could adversely affect our operations and financial performance. To the extent these events impact one or more of our key suppliers, our operations and financial performance could be materially adversely affected through lost sales. Such events could also cause US agencies and insurance companies to modify reimbursement policies which could result in lost sales, reduced revenues and otherwise adversely affect our financial performance.",
            "type": "paragraph"
        },
        {
            "id": 70,
            "context": "Our ability to finance our business may be materially adversely affected by global geopolitical conditions including those resulting from the ongoing Russia-Ukraine conflict, the Israel-Hamas conflict and efforts by terrorist organizations to disrupt global shipping patterns. Global markets are experiencing volatility and disruption as a result of the geopolitical instability resulting from the ongoing Russia-Ukraine conflict, the Israel-Hamas conflict and efforts by terrorist organizations to disrupt global shipping patterns. The invasion of Ukraine by Russia, the Israel-Hamas conflict and efforts to disrupt shipping through the Suez Canal and the resulting measures that have been taken, and could be taken in the future, by NATO, the United States, the United Kingdom, the European Union, Israel and other countries have created global security concerns that could have a lasting impact on regional and global economies and financial markets. Although the length and impact of the ongoing conflicts and any sanctions imposed are highly unpredictable, they could lead to market disruptions, including significant volatility in commodity prices, credit and capital markets and lead to instability and lack of liquidity in capital markets, adversely impacting our ability to finance our operations.",
            "type": "paragraph"
        },
        {
            "id": 71,
            "context": "Risks Related to Regulation\nOur products may be subject to product liability legal claims, which could have an adverse effect on our business, results of operations and financial condition. Certain of our products provide applications that relate to patient clinical information. Any failure by our products to provide accurate and timely information concerning patients, their medication, treatment and health status, generally, could result in claims against us which could materially and adversely impact our financial performance, industry reputation and ability to market new systems. In addition, a court or government agency may take the position that our delivery of health information directly, including through licensed practitioners, or delivery of information by a third party site that a consumer accesses through our websites, exposes us to assertions of malpractice, other personal injury liability, or other liability for wrongful delivery/handling of healthcare services or erroneous health information. We anticipate that in the future we will maintain insurance to protect against claims associated with the use of our products as well as liability limitation language in our end-user license agreements, but there can be no assurance that our insurance coverage or contractual language would adequately cover any claim asserted against us. A successful claim brought against us in excess of or outside of our insurance coverage could have an adverse effect on our business, results of operations and financial condition. Even unsuccessful claims could result in our expenditure of funds for litigation and management time and resources.",
            "type": "paragraph"
        },
        {
            "id": 72,
            "context": "There is significant uncertainty in the healthcare industry in which we operate, and we are subject to the possibility of changing government regulation, which may adversely impact our business, financial condition and results of operations. The healthcare industry is subject to changing political, economic and regulatory influences that may affect the procurement processes and operation of healthcare facilities. During the past several years, the healthcare industry has been subject to an increase in governmental regulation of, among other things, reimbursement rates and certain capital expenditures.",
            "type": "paragraph"
        },
        {
            "id": 73,
            "context": "Laws reforming the U.S. healthcare system may have an impact on our business. Various legislators have announced that they intend to examine proposals to reform certain aspects of the U.S. healthcare system. Healthcare providers may react to these proposals, and the uncertainty surrounding such proposals, by curtailing or deferring investments, including those for our systems and related services. Cost-containment measures instituted by healthcare providers as a result of regulatory reform or otherwise could result in a reduction of the allocation of capital funds. Such a reduction could have an adverse effect on our ability to sell our systems and related services. On the other hand, changes in the regulatory environment have increased and may continue to increase the needs of healthcare organizations for cost-effective data management and thereby enhance the overall market for healthcare management information systems. We cannot predict what effect, if any, such proposals or healthcare reforms might have on our business, financial condition and results of operations.",
            "type": "paragraph"
        },
        {
            "id": 74,
            "context": "We have taken steps to modify our products, services and internal practices as necessary to facilitate our compliance with applicable regulations, but there can be no assurance that we will be able to do so in a timely or complete manner. Achieving compliance with these regulations could be costly and distract management\u2019s attention and divert other company resources, and any noncompliance by us could result in civil and criminal penalties.",
            "type": "paragraph"
        },
        {
            "id": 75,
            "context": "Compliance with changing regulation of corporate governance and public disclosure will result in significant additional expenses. Changing laws, regulations, and standards relating to corporate governance and public disclosure for public companies, including the Sarbanes-Oxley Act of 2002 and various rules and regulations adopted by the Securities and Exchange Commission (the \u201cSEC\u201d), are creating uncertainty for public companies. Our Company\u2019s management will need to invest significant time and financial resources to comply with both existing and evolving requirements for public companies, which will lead, among other things, to significantly increased general and administrative expenses and a certain diversion of management time and attention from revenue generating activities to compliance activities.",
            "type": "paragraph"
        },
        {
            "id": 76,
            "context": "We may be subject to false or fraudulent claim laws. There are numerous federal and state laws that forbid submission of false information or the failure to disclose information in connection with submission and payment of physician claims for reimbursement. Any failure of our services to comply with these laws and regulations could result in substantial liability including, but not limited to, criminal liability, could adversely affect demand for our services and could force us to expend significant capital, research and development and other resources to address the failure. Errors by us or our systems with respect to entry, formatting, preparation or transmission of claim information may be determined or alleged to be in violation of these laws and regulations. Determination by a court or regulatory agency that our services violate these laws could subject us to civil or criminal penalties, invalidate all or portions of some of our client contracts, require us to change or terminate some portions of our business, require us to refund portions of our services fees, cause us to be disqualified from serving clients doing business with government payers and have an adverse effect on our business.",
            "type": "paragraph"
        },
        {
            "id": 77,
            "context": "We are subject to the Stark Law, which may result in significant penalties. Provisions of the Omnibus Budget Reconciliation Act of 1993 (42 U.S.C. \u00a7 1395nn) (the \u201cStark Law\u201d) prohibit referrals by a physician of \u201cdesignated health services\u201d which are payable, in whole or in part, by Medicare or Medicaid, to an entity in which the physician or the physician\u2019s immediate family member has an investment interest or other financial relationship, subject to several exceptions. Unlike the Fraud and Abuse Law, the Stark Law is a strict liability statute. Proof of intent to violate the Stark Law is not required. The Stark Law also prohibits billing for services rendered pursuant to a prohibited referral. Several states have enacted laws similar to the Stark Law. These state laws may cover all (not just Medicare and Medicaid) patients. Many federal healthcare reform proposals in the past few years have attempted to expand the Stark Law to cover all patients as well. As with the Fraud and Abuse Law, we consider the Stark Law in planning our products, marketing and other activities, and believe that our operations are in compliance with the Stark Law. If we violate the Stark Law, our financial results and operations could be adversely affected. Penalties for violations include denial of payment for the services, significant civil monetary penalties, and exclusion from the Medicare and Medicaid programs.",
            "type": "paragraph"
        },
        {
            "id": 78,
            "context": "We are Required to Comply with Medical Device Reporting (MDR) and We Must Report Certain Malfunctions, Deaths and Serious Injuries Associated with Our Medical Device Which Can Result In Voluntary Corrective Actions, Mandatory Recall or FDA Enforcement Actions. Under applicable FDA MDR regulations, medical device manufacturers are required to submit information to the FDA when they receive a report or become aware that a device has or may have caused or contributed to a death or serious injury or has or may have a malfunction that would likely cause or contribute to death or serious injury if the malfunction were to recur.",
            "type": "paragraph"
        },
        {
            "id": 79,
            "context": "All manufacturers placing medical devices on the market in the European Economic Area and the United States are legally bound to report any serious or potentially serious incidents involving devices they produce or sell to the regulatory agency, or Competent Authority, in whose jurisdiction the incident occurred.",
            "type": "paragraph"
        },
        {
            "id": 80,
            "context": "If our products fail to comply with evolving government and industry standards and regulations, we may have difficulty selling our products. We may be subject to additional federal and state statutes and regulations in connection with offering services and products via the Internet. On an increasingly frequent basis, federal and state legislators are proposing laws and regulations that apply to Internet commerce and communications. Areas being affected by these regulations include user privacy, pricing, content, taxation, copyright protection, distribution, and quality of products and services. To the extent that our products and services are subject to these laws and regulations, the sale of our products and services could be harmed.",
            "type": "paragraph"
        },
        {
            "id": 81,
            "context": "Risks related to our Common Stock\nThere is not now, and there may never be, an active market for our common stock. Our common stock is listed on the OTCQB level of the OTC Market under the symbol \u201cUSAQ,\u201d but there is no active trading market for our common stock. There can be no assurance that an active trading market for our securities will develop, or that if one develops, that it will be sustained. The trading market for securities of companies listed on the OTC Market is substantially less liquid than the average trading market for companies listed on a national securities exchange. In addition, our ability to raise capital will be adversely affected by a listing on the OTC Market, as compared to a listing on a national securities exchange.",
            "type": "paragraph"
        },
        {
            "id": 82,
            "context": "Our stock price is likely to be highly volatile because of several factors, including a limited public float.\nThe market price of our common stock has been volatile and is likely to be highly volatile in the future. You may not be able to resell shares of our common stock following periods of volatility because of the market\u2019s adverse reaction to volatility.\nFactors that could cause such volatility include, among other things:\n\n| \u25cf | actual or anticipated fluctuations in our operating results; |\n| \u25cf | the limited number of securities analysts covering us and distributing research and recommendations about us; |\n| \u25cf | the low public float for our common stock; |",
            "type": "table"
        },
        {
            "id": 83,
            "context": "| \u25cf | the low trading volume of our common stock; |\n| \u25cf | announcements concerning our business or those of our competitors; |\n| \u25cf | actual or perceived limitations on our ability to raise capital when we require it, and to raise such capital on favorable terms; |\n| \u25cf | conditions or trends in our industry; |\n| \u25cf | litigation; |\n| \u25cf | changes in market valuations of similar companies; |\n| \u25cf | future sales of common stock; |\n| \u25cf | departure of key personnel or failure to hire key personnel; and |\n| \u25cf | general market conditions. |",
            "type": "table"
        },
        {
            "id": 84,
            "context": "Any of these factors could have a significant and adverse impact on the market price of our common stock. In addition, the stock market in general has at times experienced extreme volatility and rapid decline that has often been unrelated or disproportionate to the operating performance of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock and/or warrants, regardless of our actual operating performance.",
            "type": "paragraph"
        },
        {
            "id": 85,
            "context": "Our stock price may be adversely impacted by natural disasters (whether or not caused by climate change), unusually adverse weather conditions, pandemic outbreaks, terrorist acts, conflicts between nations and terrorist organizations, and the response of the governments of the countries affected by such occurrences.",
            "type": "paragraph"
        },
        {
            "id": 86,
            "context": "Military or other conflicts such as those in Ukraine, the Middle East or elsewhere, natural disasters, unusually adverse weather conditions and pandemic outbreaks may lead to increased volume and price volatility for publicly traded securities, or affect the operations or financial condition of companies, and lead to national, regional or international economic disruptions and economic uncertainty, any of which could adversely impact the price of our common stock.",
            "type": "paragraph"
        },
        {
            "id": 87,
            "context": "Our common stock is subject to the \u201cPenny Stock\u201d Rules of the SEC, which makes transactions in our stock cumbersome and may reduce the value of an investment in our stock. The SEC has adopted Rule 15g-9 which establishes the definition of a \u201cpenny stock,\u201d for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (a) that a broker or dealer approve a person\u2019s account for transactions in penny stocks; and (b) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.",
            "type": "paragraph"
        },
        {
            "id": 88,
            "context": "In order to approve a person\u2019s account for transactions in penny stocks, the broker or dealer must: (a) obtain financial information and investment experience and objectives of the person; and (b) make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.",
            "type": "paragraph"
        },
        {
            "id": 89,
            "context": "The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the Commission relating to the penny stock market, which, in highlight form: (a) sets forth the basis on which the broker or dealer made the suitability determination; and (b) that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Generally, brokers may be less willing to execute transactions in securities subject to the \u201cpenny stock\u201d rules. This may make it more difficult for investors to dispose of our common shares and cause a decline in the market value of our stock.",
            "type": "paragraph"
        },
        {
            "id": 90,
            "context": "Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.",
            "type": "paragraph"
        },
        {
            "id": 91,
            "context": "Shares eligible for future sale may adversely affect the market. Substantially all of the outstanding shares of our common stock in addition to the shares issuable upon conversion of our outstanding convertible notes are freely tradable without restriction or registration under the Securities Act or otherwise eligible sale under Rule 144 promulgated under the Securities Act, subject to certain limitations. In general, pursuant to Rule 144, non-affiliate stockholders may sell freely after six months, subject only to the current public information requirement. Affiliates may sell after six months, subject to the Rule 144 volume, manner of sale (for equity securities), current public information, and notice requirements. Of the 10,215,508 shares of our common stock outstanding as of March 27, 2024, approximately 1,644,169 shares in addition to the approximately 8,571,339 shares issuable upon conversion of $1,146,000 convertible notes are tradable without restriction and the balance are restricted securities which may be sold in accordance with Rule 144. Given the limited trading of our common stock, resale of even a small number of shares of our common stock pursuant to Rule 144 or an effective registration statement, may adversely affect the market price of our common stock.",
            "type": "paragraph"
        },
        {
            "id": 92,
            "context": "Our sole director and officer controls a majority of the votes which may be cast at a meeting of our stockholders. In addition to the common stock owned by our sole director and officer, he owns shares of our Series A Preferred Stock which have the right to vote on all issues presented to our common stockholders. Taking into account the votes he is eligible to cast by virtue of the number of shares of our common stock and Series A Preferred Stock held by our sole officer and director, he controls a majority of the votes which may be cast at a meeting of our stockholders, and therefore controls our operations and will have the ability to control all matters submitted to stockholders for approval. This stockholder thus has complete control over our management and affairs. Accordingly, his ownership may have the effect of impeding a merger, consolidation, takeover or other business consolidation, or discouraging a potential acquirer from making a tender offer for our common stock, which may further affect its liquidity.",
            "type": "paragraph"
        },
        {
            "id": 93,
            "context": "Under our Certificate of Incorporation, our director has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to common stockholders and with the ability to adversely affect stockholder voting power and perpetuate the board\u2019s control over our company.",
            "type": "paragraph"
        },
        {
            "id": 94,
            "context": "Our director may authorize the issuance of preferred stock in one or more series with such limitations and restrictions as he may determine, in his sole discretion, with no further authorization by security holders required for the issuance of such shares. Our director may determine the specific terms of the preferred stock, including: designations; preferences; conversions rights; cumulative, relative; participating; and optional or other rights, including: voting rights; qualifications; limitations; or restrictions of the preferred stock. Our sole director has exercised this authority to authorize the Series A Preferred Stock which, taking into account the votes he is eligible to cast by virtue of the number of shares of our common stock and Series A Preferred Stock he holds, our sole director controls a majority of the votes which may be cast at a meeting of our stockholders, and therefore has the ability to control all matters submitted to stockholders for approval.",
            "type": "paragraph"
        },
        {
            "id": 95,
            "context": "The issuance of preferred stock may adversely affect the voting power and other rights of the holders of common stock. Preferred stock may be issued quickly with terms calculated to discourage, make more difficult, delay or prevent a change in control of our company or make removal of management more difficult. As a result, the Board of Directors\u2019 ability to issue preferred stock may discourage the potential hostile acquirer, possibly resulting in beneficial negotiations. Negotiating with an unfriendly acquirer may result in terms more favorable to us and our stockholders. Conversely, the issuance of preferred stock may adversely affect the market price of, and the voting and other rights of the holders of the common stock. We presently have no plans to issue any preferred stock.",
            "type": "paragraph"
        },
        {
            "id": 96,
            "context": "We incur significant costs as a result of operating as a public company and our management will have to devote substantial time to public company compliance obligations. The Sarbanes-Oxley Act of 2002, as well as rules subsequently implemented by the SEC and the national stock exchanges, have imposed various requirements on public companies, including requiring changes in corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance requirements and any new requirements that the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 may impose on public companies. Moreover, these rules and regulations, along with compliance with accounting principles and regulatory interpretations of such principles, have increased and will continue to increase our legal, accounting and financial compliance costs and have made and will continue to make some activities more time- consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantial costs to maintain the same or similar coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or our board committees, or as executive officers. We will evaluate the need to hire additional accounting and financial staff with appropriate public company experience and technical accounting and financial knowledge. We estimate the additional costs to be incurred as a result of being a public company to be in excess of $150,000 annually.",
            "type": "paragraph"
        },
        {
            "id": 97,
            "context": "Effective internal controls are necessary for us to provide reliable financial reports and to effectively prevent fraud. Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. Based on our assessment, we have concluded that our internal controls over financial reporting were not effective as of December 31, 2023, due to lack of an oversight committee and lack of segregation of duties. Management will consider the need to add personnel and implement improved review procedures.",
            "type": "paragraph"
        },
        {
            "id": 98,
            "context": "Our system of internal control over financial reporting is not effective and we need to take remedial measures to improve our internal control over financial reporting. Remedial measures will likely require hiring additional personnel. We cannot assure our stockholders that the measures we will take to remediate areas in need of improvement will be successful or that we will implement and maintain adequate controls over our financial processes and reporting in the future. If we are unable to maintain appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our common stock.",
            "type": "paragraph"
        },
        {
            "id": 99,
            "context": "Because we do not intend to pay any cash dividends on our common stock, our stockholders will not be able to receive a return on their shares unless they sell them. We have not declared or paid any cash dividends on our common stock nor do we anticipate paying any in the foreseeable future. Furthermore, we expect to retain any future earnings to finance our operations and expansion. The payment of cash dividends in the future will be at the discretion of our Board of Directors and will depend upon our earning levels, capital requirements, any restrictive loan covenants and other factors the Board considers relevant. Unless we pay dividends, our stockholders will not be able to receive a return on their shares unless they sell them. We cannot assure you that you will be able to sell shares when you desire to do so.",
            "type": "paragraph"
        },
        {
            "id": 100,
            "context": "We are a \u201cSmaller Reporting Company\u201d with reduced disclosure requirements which may make our common stock less attractive to investors. We are a \u201csmaller reporting company.\u201d As a \u201csmaller reporting company,\u201d the disclosure we are required to provide in our SEC filings are less than it would be if we were not a \u201csmaller reporting company.\u201d Specifically, \u201csmaller reporting companies\u201d are able to provide simplified executive compensation disclosures in their filings; are exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act of 2002 requiring that independent registered public accounting firms provide an attestation report on the effectiveness of internal control over financial reporting and have certain other decreased disclosure obligations in their SEC filings, including, among other things, being permitted to provide two years of audited financial statements in annual reports rather than three years. Decreased disclosures in our SEC filings due to our status as a \u201csmaller reporting company\u201d may make it harder for investors to analyze the Company\u2019s results of operations and financial prospects which may make our common stock less attractive, which may result in a less active trading market, higher volatility and a lower price for our common stock.",
            "type": "paragraph"
        },
        {
            "id": 101,
            "context": "Limitations on director and officer liability and indemnification of our officers and directors by our articles of incorporation, as amended, and by-laws it may discourage stockholders from bringing suit against an officer or director. Our articles of incorporation, as amended, and bylaws provide, with certain exceptions as permitted by Nevada law, that a director or officer shall not be personally liable to us or our stockholders for breach of fiduciary duty as a director or officer, unless the director or officer committed both a breach of fiduciary duty and such breach was accompanied by intentional misconduct, fraud or knowing violation of law. These provisions may discourage stockholders from bringing suit against a director or officer for breach of fiduciary duty and may reduce the likelihood of derivative litigation brought by stockholders on behalf of us against a director or officer.",
            "type": "paragraph"
        },
        {
            "id": 102,
            "context": "We are responsible for the indemnification of our officers and directors. Should our officers and/or directors require us to contribute to their defense in an action brought against them in their capacity as such, we may be required to spend significant amounts of our capital. Our articles of incorporation, as amended, and bylaws also provide for the indemnification of our directors, officers, employees, and agents, under certain circumstances, against attorney\u2019s fees and other expenses incurred by them in any litigation to which they become a party arising from their association with or activities on behalf of us. In addition, we have entered into an indemnification agreement with our Chief Executive Officer. This indemnification policy could result in substantial expenditures, which we may be unable to recoup. If these expenditures are significant or involve issues which result in significant liability for our key personnel, we may be unable to continue operating as a going concern.",
            "type": "paragraph"
        },
        {
            "id": 103,
            "context": "None.\n We are currently not a party to any material legal or administrative proceedings and are not aware of any pending legal or administrative proceedings against us. We may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of our business.",
            "type": "paragraph"
        },
        {
            "id": 104,
            "context": "PART II\n Our common stock is subject to quotation on the OTCQB venture market under the symbol USAQ. The following table shows the high and low bid prices for our common stock during the fiscal years 2023 and 2022 as reported by the OTC Market. These prices reflect inter-dealer quotations without adjustments for retail markup, markdown or commission, and do not necessarily represent actual transactions.",
            "type": "paragraph"
        },
        {
            "id": 105,
            "context": "| Price Range |\n| Period | High | Low |\n| Year Ended December 31, 2023: |\n| First Quarter | $ | 0.398 | $ | 0.11 |\n| Second Quarter | $ | 0.247 | $ | 0.065 |\n| Third Quarter | $ | 0.198 | $ | 0.0315 |\n| Fourth Quarter | $ | 0.09 | $ | 0.016 |\n| Year Ended December 31, 2022: |\n| First Quarter | $ | 0.75 | $ | 0.30 |\n| Second Quarter | $ | 0.58 | $ | 0.30 |\n| Third Quarter | $ | 0.40 | $ | 0.12 |\n| Fourth Quarter | $ | 0.18 | $ | 0.12 |",
            "type": "table"
        },
        {
            "id": 106,
            "context": "Holders\nOn March 27, 2024, there were approximately 650 holders of record of our common stock. The number of record holders does not include persons who held our common stock in nominee or \u201cstreet name\u201d accounts through brokers. Dividend Policy. We have neither declared nor paid any cash dividends on either preferred or common stock. For the foreseeable future, we intend to retain any earnings to finance the development and expansion of our business and do not anticipate paying any cash dividends on our preferred or common stock. Any future determination to pay dividends will be at the discretion of the Board of Directors and will be dependent upon then existing conditions, including its financial condition, results of operations, capital requirements, contractual restrictions, business prospects, and other factors that the Board of Directors considers relevant.",
            "type": "paragraph"
        },
        {
            "id": 107,
            "context": "Securities Authorized for Issuance Under Equity Compensation Plans\nIn 2020 we adopted an Equity Incentive Plan which authorizes grants with respect to up to 2,000,000 shares of our common stock. No grants have been made pursuant to the plan.\nRecent Sales of Unregistered Equity Securities\nAll sales of unregistered securities made by us during 2023 were previously reported.\nPurchases of Our Equity Securities\nNo repurchases of our common stock were made by us during the fiscal year ended December 31, 2023.\n\n The following discussion and analysis of our financial condition and result of operations contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the \u201cRisk Factors\u201d section of this Report. Actual results may differ materially from those contained in any forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential\u201d or \u201ccontinue,\u201d the negative of such terms or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Report to conform such statements to actual results or to changes in our expectations.",
            "type": "paragraph"
        },
        {
            "id": 108,
            "context": "The following discussion and analysis of financial condition and results of operations relates to the operations and financial condition reported in the consolidated financial statements of QHSLab, Inc. and its subsidiaries for the years ended December 31, 2023 and 2022 and should be read in conjunction with such consolidated financial statements and related notes included in this report.",
            "type": "paragraph"
        },
        {
            "id": 109,
            "context": "Overview We are a medical device technology and software as a service (SaaS) company focused on enabling primary care physicians (PCP\u2019s) and other healthcare providers to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures. In some cases, the products we provide our physician clients will enable them to diagnose and treat patients with chronic diseases which they historically have referred to specialists, allowing them to increase their practice revenue. As part of our mission, we are providing PCPs and other healthcare providers with the software, training and devices necessary to allow them to treat their patients using value-based healthcare, informatics and personalized medicine. Our digital healthcare, clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, to address chronic care and preventive medicine and are reimbursable to the medical practice.",
            "type": "paragraph"
        },
        {
            "id": 110,
            "context": "Increasingly, regulators and insurance companies have come to recognize what health care technologists have been saying for nearly 15 years, which is that most chronic conditions are better managed with more frequent and short encounters often without a physician\u2019s direct participation, rather than infrequent visits. More health insurers are have realized that AI enabled digital medicine technologies such as those provided through QHSLab can provide the necessary encounters to foster patient compliance in between visits to a physician.",
            "type": "paragraph"
        },
        {
            "id": 111,
            "context": "In November 2020, we began shipping AllergiEnd\u00ae diagnostic related products and immunotherapy treatments to PCPs in response to their requests based upon courses of treatment recommended for their patients building on the capabilities of QHSLab, our primary SaaS tool. It is estimated, based on the national average payment data for the reimbursement codes for allergy testing and allergen immunotherapy that our PCP customers generated approximately $3,686,150 in revenues utilizing our products during the year ended 2023, of which $2.76 million was the result of providing allergy diagnostic tests to patients and approximately $0.93 million was the result of providing allergen immunotherapy treatments.",
            "type": "paragraph"
        },
        {
            "id": 112,
            "context": "Based on the success of PCPs and other healthcare providers using our QHSLab allergy diagnostics combined with the products acquired from MedScience, we intend to increase our revenues by charging physicians a monthly subscription fee for the use of QHSLab and soliciting additional healthcare providers to increase their revenues by using our proven revenue generating QHSLab and AllergiEnd\u00ae line of products. We also plan to introduce additional point of care diagnostics and treatments, and digital medicine programs that providers can use and prescribe in their practices. In all cases, providers will be paid under existing government and private insurance programs, based upon analyses conducted utilizing QHSLab and treatments provided as a result of such analyses.",
            "type": "paragraph"
        },
        {
            "id": 113,
            "context": "Our ability to operate profitably is determined by our ability to generate revenues from the licensing of our QHSLab software and the sale of diagnostic related products and treatment protocols and the provision of services through our QHSLab system. Currently, we are generating revenues from the sale of AllergiEnd\u00ae diagnostic related products and immunotherapy treatments. Our ability to generate a profit from these sales is determined by our ability to increase the number of physicians using these products. We will continue to upgrade QHSLab in an effort to increase the number of products sold based upon the services it can provide and for which we are able to charge a fee for its use.",
            "type": "paragraph"
        },
        {
            "id": 114,
            "context": "Operational Highlights\nResults of Operations during the year ended December 31, 2023 as compared to the year ended December 31, 2022\nRevenues During the fourth quarter of 2020 we began to sell the AllergiEnd\u00ae Products, consisting of AllergiEnd\u00ae Allergy Diagnostics and Allergen Immunotherapy treatments, to physicians. During the second quarter of 2022, we began to enter into SaaS subscription agreements to provide physicians with access to our proprietary internally-developed QHSLab platform software that provides clinical decision support and patient monitoring for numerous chronic conditions seen in primary care settings including allergy, asthma, mental health, obesity and long COVID for example. During the fourth quarter of 2022, we began entering into Integrated Service Program agreements to provide physicians\u2019 offices with agreed-upon administrative, billing and support services utilizing our QHSLab platform software.",
            "type": "paragraph"
        },
        {
            "id": 115,
            "context": "For the year ended December 31, 2023, we generated revenues of $1,408,995 compared to $1,243,186 of revenues in 2022. Revenues in 2023 were primarily driven by sales of Allergy Diagnostic Kits of $666,600 and Immunotherapy Treatment services of $363,184 as we continued to expand the roll-out of our product lines and customer base. At the end of the second quarter of 2022, we launched our Subscription Revenue line. For the year ended December 31, 2023, we generated $72,200 of revenues from this line compared to $18,654 for the year ended December 31, 2022. During the end of 2022, we also initiated the Integrated Service Program product line that did not exist during most of 2022. During the year ended of 2023, this new service generated revenue of $270,022.",
            "type": "paragraph"
        },
        {
            "id": 116,
            "context": "Our revenues consisted of the following:\n\n| For the Years Ended |\n| December 31, |\n| 2023 | 2022 |\n| Allergy Diagnostic Kit Sales | $ | 666,600 | $ | 685,062 |\n| Immunotherapy Treatment Sales | 363,184 | 484,411 |\n| Subscription Revenue | 72,200 | 18,654 |\n| Integrated Service Program Revenue | 270,022 | 8,137 |\n| Training & Other Revenue | 4,650 | 11,288 |\n| Shipping and handling | 32,339 | 35,634 |\n| Total revenue | $ | 1,408,995 | $ | 1,243,186 |",
            "type": "table"
        },
        {
            "id": 117,
            "context": "Cost of Revenues and Gross Profit Cost of revenues consists of the cost of the AllergiEnd\u00ae test kits and allergen immunotherapy pharmacy prepared treatment sets, shipping costs to our customers as well as labor expenses directly related to product sales and the amortization of our capitalized software.",
            "type": "paragraph"
        },
        {
            "id": 118,
            "context": "For the years ended December 31, 2023 and 2022, cost of revenues was $615,388 and $623,667, respectively. The Company generated a gross profit of $793,607, for the year ended December 31, 2023 and $619,519, in 2022. Gross margin increased from 49.8% during the year ended December 31, 2022 to 56.3% during the year ended December 31, 2023. The increase in gross margin was attributable to a combination of changes in the product mix and improved cost structure since the acquisition of intangible assets from MedScience during the quarter ended June 30, 2021.",
            "type": "paragraph"
        },
        {
            "id": 119,
            "context": "As we continue to introduce new products at an early stage in our development cycle, the gross margins may vary significantly between periods, due, among other things, to differences among our customers and products sold, customer negotiating strengths, and product mix.\nSales and Marketing Sales and marketing expenses consist primarily of costs associated with selling and marketing our products to PCPs, principally ongoing sales efforts to recruit new PCPs and maintain our relationships with PCPs already using our software and products. These expenses include employee compensation and costs of consultants.",
            "type": "paragraph"
        },
        {
            "id": 120,
            "context": "For the year ended December 31, 2023, sales and marketing expenses totaled $488,537, a decrease of $41,780, compared to $530,317 for the year ended December 31, 2022. The decreases in sales and marketing expenses for the year ended December 31, 2023 compared to 2022 relates to the shift of marketing efforts to more internal sales and marketing personnel who are proving to be more cost effective than independent sales representatives offset by an increase in marketing spend in connection with the launch of the Integrated Service Program and Subscription Revenue products. We expect our sales and marketing expenses to increase as we seek to build our customer base and launch additional products. Nevertheless, if we are successful in onboarding a sufficient number of PCPs and maintaining our relationships with these PCPs once they begin to distribute our products, selling and marketing expenses could decrease as a percentage of revenues, though we may increase our marketing efforts as funds become available.",
            "type": "paragraph"
        },
        {
            "id": 121,
            "context": "General and Administrative\nGeneral and administrative expenses consist primarily of costs associated with operating a business including accounting, legal and management consulting fees.\nFor the year ended December 31, 2023, general and administrative expenses totaled $259,108, a decrease of $128,404, compared to $387,512 for the year ended December 31, 2022.\nThe decrease is primarily due to decreased fees associated with legal, investor relations and management consulting services combined with a decrease in bad debt expense following the creation of the bad debt reserve in the second quarter of 2022.\nResearch and Development\nResearch and development (\u201cR&D\u201d) expenses includes expenses incurred in connection with the research and development of our medical device technology solution, including software development. R&D costs are expensed as they are incurred.\nFor the year ended December 31, 2023, R&D expenses totaled $214,008, which is an increase of $23,891, compared to $190,117 for the year ended December 31, 2022. The increases in R&D expenses for the year ended December 31, 2023, as compared to 2022, were driven by the completion of testing of our QHSLab platform software. As a result, the spending on development is no longer being capitalized as the software is now in post-implementation stages. Any future development that may result in substantial enhancements or additional functionality for all users will be considered for capitalization as appropriate.",
            "type": "paragraph"
        },
        {
            "id": 122,
            "context": "We expect that our R&D expenses will increase as we invest in and expand our operations and further develop new products and services as part of the Company\u2019s growth strategy.\nOther Income and Expense\nFor the year ended December 31, 2023, interest expense decreased by $202,948 to $230,494 from $433,442 for the year ended December 31, 2022. The decrease was due to timing of the amortization of debt issuance costs including legal fees and warrants issued in connection with certain of our convertible notes payable. Interest expense during the year ended 2023 included interest on the outstanding debt as well as the amortization of debt issuance costs including legal fees and warrants issued in connection with the second Mercer note issued in July 2022 (\u201cSecond OID Note\u201d) which was lower than the amortization of debt issuance costs including legal fees and warrants issued in connection with the first Mercer note issued in August 2021 (\u201cFirst OID Note\u201d). The amortization of those costs, which are non-cash expenses, during the year ended December 31, 2023 totaled $61,836, or 27% of interest expense and $254,182, or 59% of the interest expense during the year ended December 31, 2022.",
            "type": "paragraph"
        },
        {
            "id": 123,
            "context": "Other income for the year ended December 31, 2023 totaled $2,290, and related to the redemption of awards on a credit card. There was no other income in the comparative period of 2022 but there was a $2,020 loss on extinguishment of debt recorded for the year ended December 31, 2022.",
            "type": "paragraph"
        },
        {
            "id": 124,
            "context": "Liquidity and Capital Resources Liquidity is a measure of a company\u2019s ability to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. On December 31, 2023, we had current assets totaling $156,132, including $51,582 of cash, $71,382 of accounts receivable, $25,181 of inventory, and $7,987 related to prepaid expenses and other current assets. At such date we had total current liabilities of $2,057,049 consisting of $78,907 in accounts payable, $196,590 in other current liabilities and $1,781,552 representing the current portions of outstanding loans and convertible notes. There were no long-term liabilities as the balance of loans payable are all in current liabilities.",
            "type": "paragraph"
        },
        {
            "id": 125,
            "context": "On December 31, 2022, we had current assets totaling $285,578, including $178,694 of cash, $47,734 of net accounts receivable, $51,840 of inventory, and $7,310 related to prepaid expenses and other current assets. At such date we had total current liabilities of $1,706,826 consisting of $85,743 in accounts payable, $116,774 in other current liabilities and $1,504,309 representing the current portions of outstanding loans and convertible notes. Our long-term liabilities balance of $174,382 is associated with the long-term portion of loans payable.",
            "type": "paragraph"
        },
        {
            "id": 126,
            "context": "We used cash of $159,627 and $350,994 in operations during the years ended December 31, 2023 and 2022, respectively. The decrease was primarily driven by lower operating expenses associated with both general and administrative and sales and marketing expenses in 2023 compared to 2022.",
            "type": "paragraph"
        },
        {
            "id": 127,
            "context": "During the third quarter of 2021, we issued a promissory note of $750,000 in connection with our acquisition of assets related to our AllergiEnd\u00ae products and an Original Issue Discount Secured Convertible Promissory Note in the principal amount of $806,000 (the \u201cFirst OID Note\u201d) along with warrants to purchase 930,000 shares of our common stock (the \u201cWarrants\u201d) for aggregate consideration of $750,000. In July 2022, to supplement our cash on hand, we issued to the holder of the First OID Note an Original Issue Discount Secured Convertible Promissory Note (the \u201cSecond OID Note\u201d) in the principal amount of $440,000 and warrants to purchase 550,000 shares of our common stock for aggregate consideration of $400,000.",
            "type": "paragraph"
        },
        {
            "id": 128,
            "context": "All amounts outstanding under the First OID Note and Second OID Note were payable on August 10, 2022, and July 19, 2023, respectively, and are secured by a lien on substantially all of our assets. We are currently in default of our obligations under the First OID Note and the Second OID Note. On February 19, 2024, the Company received the most recent notice from the manager of Mercer Street Global Opportunity Fund, LLC, the holder of the First and Second OID Notes, that it agreed to forebear from exercising any rights it might have as a result of any defaults under the First OID Note, the Second OID Note and the related documents between the Company and the Fund, provided that it reserved all of its rights.",
            "type": "paragraph"
        },
        {
            "id": 129,
            "context": "Plan of Operation and Funding The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We had an accumulated deficit of $3,983,258 at December 31, 2023, generated net losses of $468,362 and $996,001 for the years ended December 31, 2023 and 2022, respectively, and used cash of $159,627 and $350,994 in operations in these periods. We are currently in default of our obligations under our OID Notes and the note incurred to acquire assets related to our AllergiEnd\u00ae products. Although we began to generate revenue during the fourth quarter of 2020, we anticipate that we will continue to generate negative cash flow for the immediate future. These factors, among others, raise substantial doubt about our ability to continue as a going concern for a reasonable period of time. Our continuation as a going concern is dependent upon our ability to obtain necessary equity or debt financing and ultimately from generating revenues and positive cash flow to continue operations and, in the interim, to convince the holders of our notes to forbear from exercising any rights they might have as a result of our defaults. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.",
            "type": "paragraph"
        },
        {
            "id": 130,
            "context": "We expect that working capital requirements will continue to be funded through a combination of our existing funds, further issuances of securities and borrowings, and that we will remain highly leveraged as we seek to expand our business. Our working capital requirements are expected to increase in line with the growth of our business, as we incur marketing expenses and the cost of building an inventory. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. In the past we have had to rely upon our principal shareholder to support our operations. More recently we have financed our operations through the proceeds from private placements of equity and debt instruments issued to third parties. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses by raising additional capital or, when available, borrowing additional funds. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders and could cause the price of our common stock to decrease. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.",
            "type": "paragraph"
        },
        {
            "id": 131,
            "context": "Our ability to obtain funds through the issuance of debt or equity is dependent upon the state of the financial markets at such time as we may seek to raise funds. The state of the capital markets may be adversely impacted by various risks and uncertainties, including, but not limited to future and current impacts of global events such as wars in the Ukraine and Israel, increases in inflation and other risks detailed in the risk factors sections detailed in this 2023 Annual Report on Form 10K.",
            "type": "paragraph"
        },
        {
            "id": 132,
            "context": "Critical Accounting Policies\nOur significant accounting policies are described in the notes to our consolidated financial statements included elsewhere in this annual report.\n\nSee \u201cIndex to Consolidated Financial Statements\u201d which appears on page F-1 of this Annual Report on Form 10-K.\n\n\nEvaluation of Disclosure Controls and Procedures As of December 31, 2023, the Company\u2019s chief executive officer/chief financial officer conducted an evaluation regarding the effectiveness of the Company\u2019s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e)) under the Exchange Act. Based upon the evaluation of these controls and procedures, our chief executive officer/chief financial officer concluded that our disclosure controls and procedures were not effective as of the end of fiscal year 2023.",
            "type": "paragraph"
        },
        {
            "id": 133,
            "context": "Management\u2019s Annual Report on Internal Control Over Financial Reporting Management is responsible for establishing and maintaining adequate internal controls over financial reporting and for the assessment of the effectiveness of those internal controls. As defined by the SEC, internal control over financial reporting is a process designed by our principal executive officer/principal financial officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements in accordance with U.S. generally accepted accounting principles.",
            "type": "paragraph"
        },
        {
            "id": 134,
            "context": "Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.",
            "type": "paragraph"
        },
        {
            "id": 135,
            "context": "Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework. Based on our assessment and those criteria, we have concluded that our internal control over financial reporting were not effective as of December 31, 2023, due to lack of an oversight committee and lack of segregation of duties. Management will consider the need to add personnel and implement improved review procedures as we begin to generate positive cash flow.",
            "type": "paragraph"
        },
        {
            "id": 136,
            "context": "This annual report does not include an attestation report of the company\u2019s registered public accounting firm regarding internal control over financial reporting. Management\u2019s report was not subject to attestation by the Company\u2019s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only Management\u2019s report in this annual report.",
            "type": "paragraph"
        },
        {
            "id": 137,
            "context": "Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting or in other factors identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the year ended December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.",
            "type": "paragraph"
        },
        {
            "id": 138,
            "context": "Inherent Limitations of the Effectiveness of Controls Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. A control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.",
            "type": "paragraph"
        },
        {
            "id": 139,
            "context": "None.\n\n| Name | Age | Title |\n| Troy Grogan | 46 | CEO, CFO and Chairman |",
            "type": "table"
        },
        {
            "id": 140,
            "context": "Troy Grogan has been our Chairman and CEO since June 2016. Mr. Grogan has a background in health promotion, healthcare technology, and medical education \u2013 originally in Australia. He was previously appointed by the Minister of Health to one of Australia\u2019s largest health systems in Sydney and served on numerous committees for over ten years. Mr. Grogan has also been involved with a US based medical device manufacturer, founded a workplace wellness company, and co-developed numerous University-affiliated Continuing Medical Education programs for physicians and healthcare providers. Mr. Grogan attended Newcastle University, studying biological sciences and the University of New England where he studied Corporate Governance.",
            "type": "paragraph"
        },
        {
            "id": 141,
            "context": "Officer\u2019s and Director\u2019s Compensation Mr. Grogan, our CEO and only executive officer, does not have an employment agreement and is not entitled to receive any compensation for services rendered prior to December 31, 2023. Given the efforts being made by Mr. Grogan on behalf of the Company and the continued growth in our business, the Company intends beginning in 2024 to accrue compensation for his services and, subject to cash availability, to pay such amounts as may accrue in his favor.",
            "type": "paragraph"
        },
        {
            "id": 142,
            "context": "Equity Awards\nWe did not grant Mr. Grogan any equity awards or stock options during the year ended December 31, 2023.\nOutstanding Equity Awards at Fiscal Year-End\nThere were no equity awards outstanding as of the year ended December 31, 2023, nor were there any securities authorized for issuance under equity compensation plans.\n\n\nSecurity Ownership The following table sets forth information concerning beneficial ownership of our common stock as of March 27, 2024 by (i) any person or group with more than 5% of our common stock, (ii) our sole director, (iii) and our sole officer and director as a \u201cgroup.\u201d",
            "type": "paragraph"
        },
        {
            "id": 143,
            "context": "Except as otherwise indicated, we believe, that each party named in the table below has sole investment and voting power with respect to his shares, subject to community property laws, where applicable. As of March 27, 2024, we had outstanding 10,215,508 shares of common stock and 1,080,092 shares of Series A Preferred Stock and 2,644,424 shares of Series A-2 Preferred Stock. Shares of Series A Preferred Stock are convertible into shares of our common stock at a conversion price of $0.05 per share, subject to certain anti-dilution adjustments. Shares of Series A-2 Preferred Stock are convertible into shares of our common stock at a conversion price of $0.16 per share, subject to certain anti-dilution adjustments. In addition, shares of common stock issuable upon exercise of options, warrants and other convertible securities anticipated to be exercisable or convertible at or within sixty days of March 27, 2024, are deemed outstanding for the purpose of computing the percentage ownership of the person holding those securities, and the group as a whole, but are not deemed outstanding for computing the percentage ownership of any other person. The address of Mr. Grogan is c/o of our company at 901 Northpoint Parkway, Suite 302, West Palm Beach, Florida 33407.",
            "type": "paragraph"
        },
        {
            "id": 144,
            "context": "| Name of Shareholder | Amount and Nature of Beneficial Ownership | Percent of Common Stock |\n| Directors and Executive Officers: |\n| Troy Grogan1 | 11,397,209 | (1) | 52.98 | % |\n| All directors and executive officers as a group (1 person) | 11,397,209 | (1) | 52.98 | % |\n| Owners of more than 5% of our outstanding shares: |\n| Mercer Street Global Opportunity Fund, LLC | 7,659,694 | (2) | 46.18 | % |",
            "type": "table"
        },
        {
            "id": 145,
            "context": "Our principal executive offices are located at 901 Northpoint Parkway Suite 302, West Palm Beach, FL 33407. We are provided our office space at no cost by an entity related to Troy Grogan.\n\nPrincipal Accounting Fees\nThe following table presents the fees for professional audit services rendered by Accell Audit and Compliance, P.A. for the audit of the Registrant\u2019s annual financial statements for the years ended December 31, 2023 and 2022.\n\n| Year Ended | Year Ended |\n| December 31, 2023 | December 31, 2022 |\n| Audit fees | $ | 64,500 | $ | 55,000 |",
            "type": "table"
        },
        {
            "id": 146,
            "context": "Section 16(a) Compliance Section 16(a) of the Securities and Exchange Act of 1934 requires the Registrant\u2019s directors and executive officers, and persons who own beneficially more than ten percent (10%) of the Registrant\u2019s Common Stock, to file reports of ownership and changes of ownership with the Securities and Exchange Commission. Copies of all filed reports are required to be furnished to the Registrant pursuant to Section 16(a). Based solely on the reports received by the Registrant and on written representations from reporting persons, the Registrant was informed that its officer and director has not filed reports required under Section 16(a). 3,4, 13D and note no sales?",
            "type": "paragraph"
        },
        {
            "id": 147,
            "context": "PART IV\n\n| Exhibit No. | Description |\n| 3.1 | Articles of Incorporation (incorporated herein by reference to Exhibit B to the Information Statement on Form 14-C filed June 21, 2021). |\n| 3.2 | Certificate of Amendment to Certificate of Incorporation to effect Name Change (incorporated herein by reference to Exhibit 3.01 to the Registrant\u2019s Current Report on Form 8-K filed on April 19, 2022). |\n| 3.3 | By-Laws (incorporated herein by reference to Exhibit C to the Information Statement on Form 14-C filed June 21, 2021). |\n| 4.1 | Certificate of Designation authorizing issuance of Series A Preferred Stock (incorporated herein by reference to Exhibit 3.01 to the Registrant\u2019s Current Report on Form 8-K filed on September 5, 2019). |\n| 4.2 | Certificate of Designation authorizing the issuance of the Series A-2 Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Report on Form 8-K filed December 30, 2021). |\n| 10.1 | Securities Purchase Agreement between QHSLab, Inc. and Mercer Street Global Opportunity Fund, LLC dated July 21, 2022 (incorporated herein by reference to Exhibit 10.1 to the Report on Form 8-K filed July 29, 2022). |\n| 10.2 | 2020 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company\u2019s Registration Statement on Form S-8 filed March 11, 2020). |\n| 10.3 | Common Stock Purchase Warrant to purchase 550,000 shares issued by QHSLab, Inc. to Mercer Street Global Opportunity Fund, LLC dated July 21, 2022 (incorporated herein by reference to Exhibit 10.3 to the Report on Form 8-K filed July 29, 2022). |\n| 10.4 | Registration Rights Agreement in favor of Mercer Street Global Opportunity Fund, LLC (incorporated herein by reference to Exhibit 10.4 to the Report on Form 8-K filed July 29, 2022). |\n| 14.1 | Code of Business Conduct and Ethics (incorporated herein by reference to Exhibit 14.1 to the Company\u2019s Report on Form 10-K filed on March 11, 2021). |\n| 19.2 | Insider Trading Policy |\n| 21.1 | Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Registrant\u2019s Current Report on Form 8-K filed on December 23, 2019). |\n| 31 | Certification of CEO and CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |\n| 32 | Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |",
            "type": "table"
        },
        {
            "id": 148,
            "context": "| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |\n| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |\n| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |\n| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |\n| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |\n| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |",
            "type": "table"
        },
        {
            "id": 149,
            "context": "ITEM 16. FORM 10-K SUMMARY\nNone.\n\nSIGNATURES\nPursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.\n\n| QHSLab, Inc. |\n| By: | /s/ Troy Grogan |\n| Troy Grogan |\n| Chief Executive Officer, Chief Financial Officer And Director |",
            "type": "table"
        },
        {
            "id": 150,
            "context": "Date: March 27, 2024\n\nQHSLAB, INC. AND SUBSIDIARIES\nINDEX TO CONSOLIDATED FINANCIAL STATEMENTS\n\n| Report of Independent Registered Public Accounting Firm | F-2 |\n| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-4 |\n| Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022 | F-5 |\n| Consolidated Statements of Stockholders\u2019 (Deficit) Equity for the Years Ended December 31, 2023 and 2022 | F-6 |\n| Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 | F-7 |\n| Notes to Consolidated Financial Statements | F-8 |",
            "type": "table"
        },
        {
            "id": 151,
            "context": "REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM\nTo the Board of Directors and\nStockholders of QHSLab, Inc.\nOpinion on the Financial Statements We have audited the accompanying consolidated balance sheets of QHSLab, Inc. (the Company) as of December 31, 2023 and 2022, and the related consolidated statements of operations, stockholders\u2019 (deficit) equity, and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes and schedules (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.",
            "type": "paragraph"
        },
        {
            "id": 152,
            "context": "Substantial Doubt about the Company\u2019s Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2, the Company has incurred net losses and negative cash flow from operations since inception. These factors, and the need for additional financing in order for the Company to meet its business plans raises substantial doubt about the Company\u2019s ability to continue as a going concern. Our opinion is not modified with respect to that matter.",
            "type": "paragraph"
        },
        {
            "id": 153,
            "context": "Basis for Opinion These financial statements are the responsibility of the Company\u2019s management. Our responsibility is to express an opinion on the Company\u2019s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.",
            "type": "paragraph"
        },
        {
            "id": 154,
            "context": "We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company\u2019s internal control over financial reporting. Accordingly, we express no such opinion.",
            "type": "paragraph"
        },
        {
            "id": 155,
            "context": "Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.",
            "type": "paragraph"
        },
        {
            "id": 156,
            "context": "3001 N. Rocky Point Dr. East Suite 200 \u25cf Tampa, Florida 33607 \u25cf 813.367.3527\n\nCritical Audit Matters The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.",
            "type": "paragraph"
        },
        {
            "id": 157,
            "context": "Impairment of Intangibles As described in Note 3 to the Company\u2019s consolidated financial statements, the Company evaluates intangible assets with finite lives for impairment when events or changes in circumstances in an impairment may exist and indefinite lives for impairment at least annually or when events or changes in circumstances indicates that an impairment may exist.",
            "type": "paragraph"
        },
        {
            "id": 158,
            "context": "We identified the Company\u2019s application of the accounting for impairment of intangibles as a critical audit matter. The principal considerations for our determination of this critical audit matter related to the high degree of subjectivity in the Company\u2019s judgments in determining the qualitative factors. Auditing these judgments and assumptions by the Company involves auditor judgment due to the nature and extent of audit evidence and effort required to address these matters.",
            "type": "paragraph"
        },
        {
            "id": 159,
            "context": "The primary procedures we performed to address this critical audit matter included the following:\n\n| \u25cf | We obtained the impairment analysis, reviewed, and determined if the Company assessed the intangible assets at the appropriate level. |\n| \u25cf | We reviewed the qualitative factors analyzed by the Company and performed an assessment of any possible indicators of impairment. |\n| \u25cf | We obtained the computation of the sum of undiscounted cash flows expected to result from the asset group and reviewed the analysis as to whether the carrying amount of the asset group is recoverable. |",
            "type": "table"
        },
        {
            "id": 160,
            "context": "| /s/ Accell Audit & Compliance, P.A. |\n| We have served as the Company\u2019s auditor since 2021. |\n| PCAOB Firm ID# 3289 |\n| Tampa, Florida |\n| March 27, 2024 |",
            "type": "table"
        },
        {
            "id": 161,
            "context": "QHSLab, Inc.\nConsolidated Balance Sheets\nAs of December 31, 2023 and 2022\n\n| December 31, 2023 | December 31, 2022 |\n| Assets |\n| Current Assets: |\n| Cash and cash equivalents | $ | 51,582 | $ | 178,694 |\n| Accounts receivable, net | 71,382 | 47,734 |\n| Inventory | 25,181 | 51,840 |\n| Prepaid expenses and other current assets | 7,987 | 7,310 |\n| Total current assets | 156,132 | 285,578 |\n| Non-current assets: |\n| Capitalized software development costs, net | 93,079 | 167,543 |\n| Intangible assets, net | 1,432,221 | 1,504,332 |\n| Total assets | $ | 1,681,432 | $ | 1,957,453 |\n| Liabilities and Stockholders\u2019 (Deficit) Equity |\n| Current Liabilities: |\n| Accounts payable | $ | 78,907 | $ | 85,743 |\n| Other current liabilities | 196,590 | 116,774 |\n| Loans payable, current portion | 546,052 | 342,391 |\n| Convertible notes payable | 1,235,500 | 1,161,918 |\n| Total current liabilities | 2,057,049 | 1,706,826 |\n| Non-current liabilities: |\n| Loans payable, non-current portion | - | 174,382 |\n| Total non-current liabilities | - | 174,382 |\n| Total liabilities | 2,057,049 | 1,881,208 |\n| Commitments and contingencies (Note 13) |\n| Stockholders\u2019 (Deficit) Equity: |\n| Preferred stock, 10,000,000 shares authorized |\n| Preferred stock Series A, $ 0.0001 par value; 1,080,092 shares issued and outstanding | 108 | 108 |\n| Preferred stock Series A-2, $ 0.0001 par value; 2,644,424 shares issued and outstanding | 264 | 264 |\n| Preferred stock | 264 | 264 |\n| Common stock, 900,000,000 shares authorized, $ 0.0001 par value; 9,735,508 and 9,315,508 shares issued and outstanding at December 31, 2023 and 2022, respectively | 974 | 932 |\n| Additional paid-in capital | 3,606,295 | 3,589,837 |\n| Accumulated deficit | ( 3,983,258 | ) | ( 3,514,896 | ) |\n| Total stockholders\u2019 (deficit) equity | ( 375,617 | ) | 76,245 |\n| Total liabilities and stockholders\u2019 (deficit) equity | $ | 1,681,432 | $ | 1,957,453 |",
            "type": "table"
        },
        {
            "id": 162,
            "context": "See accompanying notes to consolidated financial statements.\n\nQHSLab, Inc.\nConsolidated Statements of Operations\nFor the Years Ended December 31, 2023 and 2022\n\n| Year Ended | Year Ended |\n| December 31, 2023 | December 31, 2022 |\n| Revenue | $ | 1,408,995 | $ | 1,243,186 |\n| Cost of revenue | 615,388 | 623,667 |\n| Gross profit | 793,607 | 619,519 |\n| Operating Expenses: |\n| Sales and marketing | 488,537 | 530,317 |\n| General and administrative | 259,108 | 387,512 |\n| Research and development | 214,008 | 190,117 |\n| Amortization | 72,112 | 72,112 |\n| Total Operating Expenses | 1,033,765 | 1,180,058 |\n| Net operating loss | ( 240,158 | ) | ( 560,539 | ) |\n| Other income (expense) |\n| Interest expense | ( 230,494 | ) | ( 433,442 | ) |\n| Other income | 2,290 | - |\n| Loss on extinguishment of debt | - | ( 2,020 | ) |\n| Loss before income taxes | ( 468,362 | ) | ( 996,001 | ) |\n| Provision on income taxes | - | - |\n| Net loss | $ | ( 468,362 | ) | $ | ( 996,001 | ) |\n| Basic and diluted net loss per share | $ | ( 0.05 | ) | $ | ( 0.11 | ) |\n| Weighted average shares outstanding (basic and diluted) | 9,416,768 | 8,997,129 |",
            "type": "table"
        },
        {
            "id": 163,
            "context": "See accompanying notes to consolidated financial statements.\n\nQHSLab, Inc.\nConsolidated Statements of Stockholders\u2019 (Deficit) Equity\nFor the Years Ended December 31, 2023 and 2022\n\n| Shares | Amount | Shares | Amount | Shares | Amount | Compensation | Capital | Deficit | (Deficit) |\n| Preferred \u2013 Stock- Series A | Preferred Stock - Series A-2 | Common Stock | Unearned Stock | Additional Paid-In | Accumulated | Total Stockholders\u2019 (Deficit) |\n| Shares | Amount | Shares | Amount | Shares | Amount | Compensation | Capital | Deficit | Equity |\n| Balance at January 1, 2022 | 1,080,092 | $ | 108 | 2,644,424 | $ | 264 | 8,756,093 | $ | 876 | $ | ( 6,968 | ) | $ | 3,348,681 | $ | ( 2,518,895 | ) | $ | 824,066 |\n| Warrants issued as deferred financing costs | - | - | - | - | - | - | - | 81,183 | - | 81,183 |\n| Shares issued for services | - | - | - | - | - | - | 6,968 | - | - | 6,968 |\n| Conversion of notes payable | - | - | - | - | 309,415 | 31 | - | 77,894 | - | 77,925 |\n| Warrants issued with conversion of notes payable | - | - | - | - | - | - | - | 2,020 | - | 2,020 |\n| Stock-based compensation expense | - | - | - | - | - | - | - | 30,084 | - | 30,084 |\n| Share purchase | - | - | - | - | 250,000 | 25 | - | 49,975 | - | 50,000 |\n| Net loss | - | - | - | - | - | - | - | - | ( 996,001 | ) | ( 996,001 | ) |\n| Balance at December 31, 2022 | 1,080,092 | $ | 108 | 2,644,424 | $ | 264 | 9,315,508 | $ | 932 | $ | - | $ | 3,589,837 | $ | ( 3,514,896 | ) | $ | 76,245 |\n| Balance | 1,080,092 | $ | 108 | 2,644,424 | $ | 264 | 9,315,508 | $ | 932 | $ | - | $ | 3,589,837 | $ | ( 3,514,896 | ) | $ | 76,245 |\n| Stock-based compensation expense | - | - | - | - | - | - | - | 6,000 | - | 6,000 |\n| Conversion of notes payable | - | - | - | - | 420,000 | 42 | - | 10,458 | - | 10,500 |\n| Net loss | - | - | - | - | - | - | - | - | ( 468,362 | ) | ( 468,362 | ) |\n| Balance at December 31, 2023 | 1,080,092 | $ | 108 | 2,644,424 | $ | 264 | 9,735,508 | $ | 974 | $ | - | $ | 3,606,295 | $ | ( 3,983,258 | ) | $ | ( 375,617 | ) |\n| Balance | 1,080,092 | $ | 108 | 2,644,424 | $ | 264 | 9,735,508 | $ | 974 | $ | - | $ | 3,606,295 | $ | ( 3,983,258 | ) | $ | ( 375,617 | ) |",
            "type": "table"
        },
        {
            "id": 164,
            "context": "See accompanying notes to consolidated financial statements.\n\nQHSLab, Inc.\nConsolidated Statements of Cash Flows\nFor the Years Ended December 31, 2023 and 2022\n\n| Year Ended | Year Ended |\n| December 31, 2023 | December 31, 2022 |\n| Operating activities |\n| Net loss | $ | ( 468,362 | ) | $ | ( 996,001 | ) |\n| Adjustments to reconcile net loss to net cash from operating activities: |\n| Allowance for doubtful accounts | 10,216 | 8,230 |\n| Amortization | 146,575 | 127,959 |\n| Amortization of debt and warrant issuance costs | 84,082 | 305,996 |\n| Stock-based compensation | 6,000 | 30,084 |\n| Shares issued for services | - | 6,968 |\n| Loss on extinguishment of debt | - | 2,020 |\n| Changes in operating assets and liabilities: |\n| Accounts receivable | ( 33,864 | ) | 14,510 |\n| Inventory | 26,659 | 13,900 |\n| Prepaid expenses and other current assets | ( 677 | ) | 15,403 |\n| Accounts payable | ( 6,836 | ) | 65,374 |\n| Other current liabilities | 76,580 | 54,563 |\n| Cash flows from operating activities | ( 159,627 | ) | ( 350,994 | ) |\n| Investing activities: |\n| Capitalized software | - | ( 37,119 | ) |\n| Cash flows from investing activities | - | ( 37,119 | ) |\n| Financing activities: |\n| Proceeds from sales of common stock | - | 50,000 |\n| Issuance of convertible notes payable | - | 400,000 |\n| Proceeds from related-party borrowings | 3,236 | - |\n| Proceeds of loan borrowings | 388,700 | 239,800 |\n| Repayments of loan borrowings | ( 359,421 | ) | ( 379,848 | ) |\n| Payment of debt issuance costs | - | ( 30,000 | ) |\n| Cash flows from financing activities | 32,515 | 279,952 |\n| Change in cash | ( 127,112 | ) | ( 108,161 | ) |\n| Cash and cash equivalents - beginning of year | 178,694 | 286,855 |\n| Cash and cash equivalents - end of period | $ | 51,582 | $ | 178,694 |\n| Supplemental disclosures of cash flow activity: |\n| Cash paid for interest | $ | 61,295 | $ | 71,785 |\n| Cash paid for taxes | $ | - | $ | - |\n| Supplemental noncash investing and financing activity: |\n| Debt and accrued interest converted to shares of common stock | $ | 10,500 | $ | 77,925 |\n| Warrants issued in conjunction with convertible note payable | $ | - | $ | 81,183 |",
            "type": "table"
        },
        {
            "id": 165,
            "context": "See accompanying notes to consolidated financial statements.\n\nQHSLab, Inc.\nNotes to Consolidated Financial Statements\nDecember 31, 2023 and 2022\nNote 1. The Company QHSLab, Inc. (the \u201cCompany\u201d or the \u201cRegistrant\u201d) was incorporated in Delaware on September 1, 1983. In 2019, the Company became engaged in value-based healthcare, informatics and algorithmic personalized medicine including digital therapeutics, behavior based remote patient monitoring, chronic care and preventive medicine. On September 23, 2021, the Company changed its state of incorporation from Delaware to Nevada. On April 19, 2022, the Company changed its name to QHSLab, Inc.",
            "type": "paragraph"
        },
        {
            "id": 166,
            "context": "The Company is a medical device technology and software-as-a-service (\u201cSaaS\u201d) company focused on enabling primary care physicians (\u201cPCP\u2019s\u201d) to increase their revenues by providing them with relevant, value-based tools to evaluate and treat chronic disease as well as provide preventive care through reimbursable procedures.",
            "type": "paragraph"
        },
        {
            "id": 167,
            "context": "Note 2. Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception and continues to have negative operating cash flows. These conditions raise substantial doubt about the Company\u2019s ability to continue as a going concern. The continuation of the Company\u2019s business is dependent upon its ability to achieve profitability and positive cash flows and, pending such achievement, future issuances of equity or other financings to fund ongoing operations. However, access to such funding may not be available on commercially reasonable terms, if at all. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.",
            "type": "paragraph"
        },
        {
            "id": 168,
            "context": "Note 3. Basis of Presentation The consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (\u201cU.S. GAAP\u201d). In the opinion of management, the accompanying audited consolidated financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows.",
            "type": "paragraph"
        },
        {
            "id": 169,
            "context": "Accounting Policies Use of Estimates: The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.",
            "type": "paragraph"
        },
        {
            "id": 170,
            "context": "Principles of Consolidation: The consolidated financial statements include the accounts of QHSLab, Inc. and its wholly owned subsidiaries USAQ Corporation, Inc. and Medical Practice Income, Inc. All significant inter-company balances and transactions have been eliminated.",
            "type": "paragraph"
        },
        {
            "id": 171,
            "context": "Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents. Cash and cash equivalents are maintained at banks believed to be stable, occasionally at amounts in excess of federally insured limits, which represents a concentration of credit risk. The Company has not experienced any losses on deposits of cash and cash equivalents to date.",
            "type": "paragraph"
        },
        {
            "id": 172,
            "context": "Accounts Receivable: The Company extends unsecured credit to its customers on a regular basis. Management monitors the payments on outstanding balances and adjusts the reserve for uncollectible balances to represent future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The Company controls its credit risk related to accounts receivable through credit approvals and monitoring, The Company had no customers that generated 10% or more of its revenue during 2023. As of December 31, 2023, two customers each comprised greater than 10% of the outstanding accounts receivable balance, one at 12.3 % and the other at 10.4 %.",
            "type": "paragraph"
        },
        {
            "id": 173,
            "context": "Inventories: Inventories are stated at the lower of cost or estimated net realizable value, on a first-in, first-out, or FIFO, basis. The Company uses actual costs to determine its cost basis for inventories. Inventories consist of only finished goods.",
            "type": "paragraph"
        },
        {
            "id": 174,
            "context": "Capitalized Software Development Costs: Software development costs for internal-use software are accounted for in accordance with Accounting Standards Codification (\u201cASC\u201d) 350-40, Internal-Use Software. Development costs that are incurred during the application development stage begin to be capitalized when two criteria are met: (i) the preliminary project stage is completed and (ii) it is probable that the software will be completed and used for its intended function. Capitalization ceases once the software is substantially complete and ready for its intended use. Costs incurred during the preliminary project stage of software development and post-implementation operating stages are expensed as incurred. Amortization is calculated on a straight-line basis over three years which is the estimated economic life of the software and is included in the cost of revenue on the consolidated statements of operations.",
            "type": "paragraph"
        },
        {
            "id": 175,
            "context": "The estimated useful lives of software are reviewed at least annually and will be tested for impairment whenever events or changes in circumstances occur that could impact the recoverability of the assets. Capitalized software development costs for internal-use software totaled $ 93,079 as of December 31, 2023 and $ 167,543 as of December 31, 2022. The Company completed testing of its internally-developed software application (\u201cQHSLab platform\u201d) at the end of the first quarter of 2022 and began to amortize the capitalized expenses on a straight-line basis over the useful life of the software. During years ended December 31, 2023 and 2022 there was $ 74,464 and $ 55,847 of amortization recognized, respectively. There were no impairments recognized during the years ended December 31, 2023 and December 31, 2022.",
            "type": "paragraph"
        },
        {
            "id": 176,
            "context": "Intangible Assets: Intangible assets represent the value the Company paid to acquire assets including a trademark, patent and web domain on June 23, 2021. The provisional allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. These assets are accounted for in accordance with ASC 350-30, Intangibles, General Intangibles Other Than Goodwill. The cost of the assets is amortized over the remaining useful life of the assets as follows:",
            "type": "paragraph"
        },
        {
            "id": 177,
            "context": "Schedule of Indefinite-Lived Intangible Assets\n\n| U.S. Method Patent | 13.4 years |\n| Web Domain | Indefinite life |\n| Trademark | Indefinite life |",
            "type": "table"
        },
        {
            "id": 178,
            "context": "The estimated useful lives and carrying value of the assets are reviewed at least annually or whenever events or circumstances occur which may result in an impact to the value of the assets. Convertible Notes Payable: The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under Accounting Standards Update No. 2020-06, Debt\u2014Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging\u2014Contracts in Entity\u2019s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity\u2019s Own Equity (\u201cASU 2020-06\u201d), which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including certain convertible instruments and contracts on an entity\u2019s own equity. ASU 2020-06 removes the separation models required for convertible debt with cash conversion features and convertible instruments with beneficial conversion features. It also removes certain settlement conditions that were required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation for convertible instruments. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt.",
            "type": "paragraph"
        },
        {
            "id": 179,
            "context": "Revenue Recognition: Pursuant to ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, the Company recognizes revenue upon transfer of control of goods or services, in an amount that reflects the consideration that is expected to be received in exchange for those goods. The Company does not allow for the return of products and therefore does not establish an allowance for returns.",
            "type": "paragraph"
        },
        {
            "id": 180,
            "context": "To determine the revenue to be recognized for transactions that the Company determines are within the scope of ASC 606, the Company follows the established five-step framework as follows:\n\n| (i) | identify the contract(s) with a customer; |\n| (ii) | identify the performance obligations in the contract(s); |\n| (iii) | determine the transaction price; |\n| (iv) | allocate the transaction price to the performance obligations in the contract(s); and |\n| (v) | recognize revenue when (or as) the Company satisfies a performance obligation. |",
            "type": "table"
        },
        {
            "id": 181,
            "context": "The Company sells allergy diagnostic-related products and immunotherapy treatments to physicians. Revenue is recognized once the Company satisfies its performance obligation which occurs at the point in time when title and possession of products have transitioned to the customer, typically upon delivery of the products.",
            "type": "paragraph"
        },
        {
            "id": 182,
            "context": "The Company includes shipping and handling fees billed to customers in revenue. The Company also generates revenue through Software-as-a-Service (SaaS) agreements whereby the Company provides physicians\u2019 practices access to its proprietary internally-developed software that provides clinical decision support and patient monitoring. The agreements provide for either monthly or annual access to the software. The access to the system begins immediately and revenue is recognized over the agreement term.",
            "type": "paragraph"
        },
        {
            "id": 183,
            "context": "The Company provides administrative, billing and support services utilizing the Company\u2019s internally-developed software. Revenue is recognized each month based on actual services provided during that month. There are several practical expedients and exemptions allowed under ASC 606 that impact timing of revenue recognition and disclosures. The Company elected to treat similar contracts as a portfolio of contracts, as allowed under ASC 606. The contracts that fall within the portfolio have the same terms and management has the expectation that the result will not be materially different from the consideration of each individual contract.",
            "type": "paragraph"
        },
        {
            "id": 184,
            "context": "Research and Development: Research and development expense is primarily related to developing and improving methods related to the Company\u2019s Software as a Service (SaaS) platform. Research and development expenses are expensed when incurred. For the years ended December 31, 2023 and 2022, there were $ 214,008 and $ 190,117 of research and development expenses incurred, respectively.",
            "type": "paragraph"
        },
        {
            "id": 185,
            "context": "Stock-based Compensation: The Company applies the fair value method of ASC 718, Share Based Payment, in accounting for its stock-based compensation. The standard states that compensation cost is measured at the grant date based on the fair value of the award and is recognized over the service period, which is usually the vesting period. The Company values stock-based compensation at the market price for the Company\u2019s common stock and other pertinent factors at the grant date.",
            "type": "paragraph"
        },
        {
            "id": 186,
            "context": "Earnings Per Common Share: Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options and warrants to purchase common stock (only if those options and warrants are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of December 31, 2023 or 2022.",
            "type": "paragraph"
        },
        {
            "id": 187,
            "context": "Income Taxes: The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.",
            "type": "paragraph"
        },
        {
            "id": 188,
            "context": "The Company has net operating losses of $ 3,983,258 which begin to expire in 2027 . Future utilization of currently generated federal and state NOL and tax credit carry forwards may be subject to a substantial annual limitation due to the ownership change limitations. The annual limitation may result in the expiration of NOL and tax credit carry-forwards before full utilization.",
            "type": "paragraph"
        },
        {
            "id": 189,
            "context": "Recently Issued Accounting Standards In June 2016, the Financial Accounting Standards Board (\u201cFASB\u201d) issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (\u201cASU 2016-13\u201d), which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been incurred. ASU 2016-13 requires the establishment of an allowance for estimated credit losses on financial assets including trade and other receivables based on historical information, current information and reasonable and supportable forecasts, at each reporting date. The new standard may result in earlier recognition of allowances for losses on trade and other receivables and other contractual rights to receive cash. The Company adopted ASU 2016-13 as of January 1, 2023, and the adoption did not have a material impact on the Company\u2019s consolidated financial statements and related disclosures.",
            "type": "paragraph"
        },
        {
            "id": 190,
            "context": "This Annual Report on Form 10-K does not discuss recent pronouncements that are not anticipated to have a current and/or future impact on or are unrelated to the Company\u2019s financial condition, results of operations, cash flows or disclosures.\n\nNote 4. Accounts Receivable Accounts receivable is recorded in the consolidated balance sheets when customers are invoiced for revenue to be collected and there is an unconditional right to receive payment. Timing of revenue recognition may differ from the timing of invoicing customers resulting in deferred revenue until the Company satisfies its performance obligation.",
            "type": "paragraph"
        },
        {
            "id": 191,
            "context": "Accounts receivable is presented net of an allowance for doubtful accounts that represents future expected credit losses over the life of the receivables based on past experience, current information and forward-looking economic considerations. The beginning and ending balances of accounts receivable, net of allowance, are as follows:",
            "type": "paragraph"
        },
        {
            "id": 192,
            "context": "Schedule of Accounts Receivable\n\n| December 31, 2023 | December 31, 2022 |\n| Accounts receivable | $ | 89,827 | $ | 55,964 |\n| Allowance for doubtful accounts | ( 18,445 | ) | ( 8,230 | ) |\n| Accounts receivable, net | $ | 71,382 | $ | 47,734 |",
            "type": "table"
        },
        {
            "id": 193,
            "context": "Note 5. Capitalized Software and Intangible Assets\nNon-current assets consist of the following at December 31, 2023 and 2022:\nSchedule of Intangible Assets\n\n| Estimated Useful Life (in years) | December 31, 2023 | December 31, 2022 |\n| Capitalized software | 3.0 | $ | 223,390 | $ | 223,390 |\n| Accumulated amortization | ( 130,311 | ) | ( 55,847 | ) |\n| Capitalized software, net | $ | 93,079 | $ | 167,543 |\n| Intangible Assets: |\n| U.S. Method Patent | 13.4 | $ | 967,500 | $ | 967,500 |\n| Web Domain | N/A | 161,250 | 161,250 |\n| Trademark | N/A | 483,750 | 483,750 |\n| Total Intangible assets | $ | 1,612,500 | $ | 1,612,500 |\n| Accumulated amortization | ( 180,279 | ) | ( 108,168 | ) |\n| Intangible assets, net | $ | 1,432,221 | $ | 1,504,332 |",
            "type": "table"
        },
        {
            "id": 194,
            "context": "Capitalized software represents the development costs for the Company\u2019s internal-use QHSLab platform software. The Company completed testing of its QHSLab platform software application at the end of the first quarter of 2022 and began to amortize the capitalized expenses on a straight-line basis over the useful life of the software. During the years ended December 31, 2023 and 2022 there was $ 74,464 and $ 55,847 of amortization expense, respectively. Amortization related to the QHSLab platform is recorded within cost of revenue on the Company\u2019s consolidated statements of operations. There were no impairments recognized during the years ended December 31, 2023 and 2022.",
            "type": "paragraph"
        },
        {
            "id": 195,
            "context": "The intangible assets represent the value the Company paid to acquire the trademark \u201cAllergiEnd\u201d, the web domain \u201cAllergiEnd.com\u201d along with the U.S. Method Patent registration relating to the allergy testing kit and related materials the Company distributes to physician clients. The Company acquired the intangible assets from MedScience Research Group as of June 23, 2021 for total consideration of $ 1,612,500 which was financed through a combination of restricted stock and a promissory note. The allocation of the purchase price to each of these assets was determined based on ASC 805-50-30, Business Combination, Related Issues, Initial Measurement. The assets are being amortized over their useful lives beginning July 1, 2021. The Trademark and Web Domain are determined to have an indefinite life and will be tested annually for impairment in accordance with ASC 350-30-35, Intangibles, General Intangibles Other Than Goodwill. There was $ 72,112 of amortization expense during each of the years ended December 31, 2023 and 2022.",
            "type": "paragraph"
        },
        {
            "id": 196,
            "context": "The Company evaluates intangible assets with infinite lives for impairment at least annually and evaluates intangible assets with finite lives when events or circumstances indicate an impairment may exist. No impairments or changes in useful lives were recognized during the years ended December 31, 2023 and 2022.",
            "type": "paragraph"
        },
        {
            "id": 197,
            "context": "Note 6. Loans Payable On June 23, 2021, the Company entered into a purchase agreement to acquire certain assets from MedScience Research Group, Inc (\u201cMedScience\u201d) (See Note 5 for additional information). As part of that purchase agreement, the Company issued a Promissory Note with a principal sum of $ 750,000 . The principal, along with associated interest, are being paid in 36 equal monthly installments that began in July 2021. The Company has deferred certain principal payments and MedScience has indicated that it would forbear taking any action but reserves all its rights under its agreement. The most recent notice of forbearance was received on February 19, 2024. The combined principal due along with accrued interest as of December 31, 2023 is $ 396,138 and as of December 31, 2022 was $ 426,451 .",
            "type": "paragraph"
        },
        {
            "id": 198,
            "context": "On November 28, 2022, the Company entered into another fixed-fee short-term loan with its merchant bank and received $ 111,300 in loan proceeds. The loan payable is due in May 2024 . The loan was repaid by the merchant bank withholding an agreed-upon percentage of payments they processed on behalf of the Company with a minimum of $ 13,776 paid every 60 days. As of December 31, 2023 and 2022, the loan balance was $ 0 and $ 93,146 , respectively.",
            "type": "paragraph"
        },
        {
            "id": 199,
            "context": "On April 21, 2023, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 162,000 in loan proceeds. The loan was repaid by the merchant bank withholding an agreed-upon percentage of payments they processed on behalf of the Company with a minimum of $ 20,538 paid every 60 days. The loan payable was due in October 2024 and repaid in full during October 2023.",
            "type": "paragraph"
        },
        {
            "id": 200,
            "context": "On October 5, 2023, the Company entered into a fixed-fee short-term loan with its merchant bank and received $ 226,700 in loan proceeds. The loan is repaid by the merchant bank withholding an agreed-upon percentage of payments they process on behalf of the Company with a minimum of $ 28,463 paid every 60 days. The loan payable is due in April 2025. As of December 31, 2023, the loan balance is $ 174,092 .",
            "type": "paragraph"
        },
        {
            "id": 201,
            "context": "Note 7. Convertible Notes Payable\nConvertible notes payable at December 31, 2023 and 2022 consist of the following:\nSchedule of Convertible Notes Payable\n\n| December 31, 2023 | December 31, 2022 |\n| Note 1 \u2013 Shareholder | $ | 100,000 | $ | 100,000 |\n| Note 2 \u2013 Mercer Note | 695,500 | 706,000 |\n| Note 3 \u2013 Mercer Note #2 | 440,000 | 440,000 |\n| Total | 1,235,500 | 1,246,000 |\n| Debt discount and issuance costs | - | ( 84,082 | ) |\n| Total convertible notes payable | 1,235,500 | 1,161,918 |\n| Less: current portion | 1,235,500 | 1,161,918 |\n| Non-current portion | $ | - | $ | - |",
            "type": "table"
        },
        {
            "id": 202,
            "context": "Note 1 \u2013 Effective May 7, 2021, the Company issued a Convertible Promissory Note in the principal amount of $ 100,000 to a shareholder (Note 1). The Note bears interest at the rate of 10 % per annum and matures on September 30, 2022 (the \u201cMaturity Date\u201d) at which date all outstanding principal and accrued and unpaid interest are due and payable. On October 1, 2022, the Maturity Date of Note 1 was extended to December 31, 2023. The Company may satisfy the Note upon maturity or Default, as defined, by the issuance of common shares at a conversion price equal to the greater of a 25% discount to the 15-day average market price of the Company\u2019s common stock or $0.50. The principal and interest accrued are convertible at any time through the maturity date of December 31, 2023 at the option of the holder using the same conversion calculation . As of December 31, 2023 and 2022, this Note had $ 26,521 and $ 16,521 , respectively, of accrued interest.",
            "type": "paragraph"
        },
        {
            "id": 203,
            "context": "Note 2 \u2013 Effective August 10, 2021, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which it issued to the investor an Original Issue Discount Secured Convertible Promissory Note (the \u201c$806,000 Note\u201d) in the principal amount of $ 806,000 and warrants to purchase 930,000 shares of the Company\u2019s common stock for aggregate consideration of $ 750,000 . In addition, pursuant to the Purchase Agreement the Company entered into a Registration Rights Agreement with the investor.",
            "type": "paragraph"
        },
        {
            "id": 204,
            "context": "The principal amount of the $ 806,000 Note and all interest accrued thereon is payable on August 10, 2022, and is secured by a lien on substantially all of the Company\u2019s assets. The $ 806,000 Note provides for interest at the rate of 5 % per annum, payable at maturity, and is convertible into common stock at a price of $ 0.65 per share. In addition to customary anti-dilution adjustments upon the occurrence of certain corporate events, the $ 806,000 Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the $ 806,000 Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such stock or common stock equivalents were sold.",
            "type": "paragraph"
        },
        {
            "id": 205,
            "context": "On November 11, 2021, Mercer Street Global Opportunity Fund, LLC (\u201cMercer Fund\u201d), converted $ 50,000 of the principal amount of the $ 806,000 Note into 76,923 shares of the Company\u2019s common stock at a price of $ 0.65 per share.",
            "type": "paragraph"
        },
        {
            "id": 206,
            "context": "The 930,000 Warrants are initially exercisable for a period of three years at a price of $ 1.25 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant. The shares issuable upon conversion of the $ 806,000 Note and exercise of the Warrants are to be registered under the Securities Act of 1933, as amended, for resale by the investor as provided in the Registration Rights Agreement. The Warrants may be exercised by means of a \u201ccashless exercise\u201d if at any time the shares issuable upon exercise of the Warrant are not covered by an effective registration statement.",
            "type": "paragraph"
        },
        {
            "id": 207,
            "context": "As a result of the issuance of a $ 440,000 Original Issue Discount Secured Convertible Promissory Note effective July 19, 2022, (Note 3) convertible into shares of the Company\u2019s common stock at a price of $ 0.20 per share, the price at which the $ 806,000 Note may be converted into shares of the Company\u2019s common stock has been reduced to $ 0.20 per share. On July 27, 2022, Mercer Fund converted $ 50,000 of the principal amount of the $ 806,000 Note into 250,000 shares of the Company\u2019s common stock at a price of $ 0.20 per share.",
            "type": "paragraph"
        },
        {
            "id": 208,
            "context": "On October 5, 2023, at the request of Mercer Fund, the Company agreed to reduce the conversion price with respect to $ 10,500 of the amounts payable pursuant to the $ 806,000 Note to two and one-half ($ 0.025 ) cents per share. The balance of the amounts payable pursuant to the $ 806,000 Note remain convertible into shares of common stock of the Company at a price of twenty ($ 0.20 ) cents per share.",
            "type": "paragraph"
        },
        {
            "id": 209,
            "context": "On February 19, 2024, the Company received the most recent notice from the manager of Mercer Fund of its agreement to forebear from the exercise of any rights it might have as a result of any defaults under the $ 806,000 Note and the related documents between the Company and the Mercer Fund, provided that the Mercer Fund reserved all of its rights under such agreements. The $ 806,000 Note continues to accrue interest at 5 %.",
            "type": "paragraph"
        },
        {
            "id": 210,
            "context": "As of December 31, 2023, all original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, have been recognized. The remaining principal balance of $ 695,500 , along with associated interest, is recorded with current liabilities on the Company\u2019s consolidated balance sheets. As of December 31, 2023, the $ 806,000 Note had $ 87,344 of accrued interest, total unamortized debt issuance costs of $ 0 , including the Warrant and the remaining discount. As of December 31, 2022, the $ 806,000 Note had $ 52,171 of accrued interest.",
            "type": "paragraph"
        },
        {
            "id": 211,
            "context": "Note 3 \u2013 Effective July 19, 2022, the Company entered into a Securities Purchase Agreement with Mercer Fund pursuant to which it issued an Original Issue Discount Secured Convertible Promissory Note (the \u201c$440,000 Note\u201d) in the principal amount of $ 440,000 and warrants to purchase 550,000 shares of the Company\u2019s common stock for aggregate consideration of $ 400,000 . In addition, pursuant to the Purchase Agreement the Company entered into a Registration Rights Agreement with Mercer Fund.",
            "type": "paragraph"
        },
        {
            "id": 212,
            "context": "The principal amount of the $ 440,000 Note and all interest accrued thereon is payable on July 19, 2023, and are secured by a lien on substantially all of the Company\u2019s assets. The $ 440,000 Note provides for interest at the rate of 5 % per annum, payable at maturity, and is convertible into common stock at a price of $ 0.20 per share. In addition to customary anti-dilution adjustments upon the occurrence of certain corporate events, the $ 440,000 Note provides, subject to certain limited exceptions, that if the Company issues any common stock or common stock equivalents, as defined in the $ 440,000 Note, at a per share price lower than the conversion price then in effect, the conversion price will be reduced to the per share price at which such stock or common stock equivalents were sold.",
            "type": "paragraph"
        },
        {
            "id": 213,
            "context": "The $ 440,000 Note provides for various events of default similar to those provided for in similar transactions, including the failure to timely pay amounts due thereunder. The $ 440,000 Note provides further that the Company will be liable to the Mercer Fund for various amounts, including the cost of a buy-in, if the Company shall default in its obligation to register the shares issuable upon conversion of the $ 440,000 Note for sale by the Mercer Fund under the Securities Act or otherwise fails to facilitate Buyer\u2019s sale of the shares issuable upon conversion of the $ 440,000 Note as required by the terms of the $ 440,000 Note.",
            "type": "paragraph"
        },
        {
            "id": 214,
            "context": "On February 19, 2024 the Company received the most recent notice from the manager of the Mercer Fund, LLC that it agreed to forebear from exercising any rights it might have as a result of any defaults under the $ 440,000 Note and the related documents between the Company and the Fund, provided that it reserved all of its rights.",
            "type": "paragraph"
        },
        {
            "id": 215,
            "context": "The 550,000 Warrants are initially exercisable for a period of three years at a price of $ 0.50 per share, subject to customary anti-dilution adjustments upon the occurrence of certain corporate events as set forth in the Warrant. The shares issuable upon conversion of the $ 440,000 Note and exercise of the Warrants are to be registered under the Securities Act of 1933, as amended, for resale by the investor as provided in the Registration Rights Agreement. The Warrants may be exercised by means of a \u201ccashless exercise\u201d if at any time the shares issuable upon exercise of the Warrant are not covered by an effective registration statement.",
            "type": "paragraph"
        },
        {
            "id": 216,
            "context": "The Registration Rights Agreement requires the Company to file with the Securities and Exchange Commission within 60 days following the closing of the issuance of the $ 440,000 Note, a registration statement (the \u201cRegistration Statement\u201d) with respect to all shares which may be acquired upon conversion of the $ 440,000 Note and exercise of the Warrant (the \u201cRegistrable Securities\u201d) and to cause the Registration Statement to be declared effective no later than 90 days after the date of the issuance of the $ 440,000 Note, provided, that if the Company is notified by the SEC that the Registration Statement will not be reviewed or is no longer subject to further review and comments, the Company shall cause the Registration Statement to be declared effective on the fifth trading day following the date on which the Company is so notified. The Company is to cause the Registration Statement to remain continuously effective until all Registrable Securities covered by such Registration Statement have been sold, or may be sold pursuant to Rule 144 without the volume or other limitations of such rule, or are otherwise not required to be registered in reliance upon the exemption in Section 4(a)(1) or 4(a)(7) under the Securities Act.",
            "type": "paragraph"
        },
        {
            "id": 217,
            "context": "The Company accounts for the allocation of its issuance costs related to its Warrants in accordance with ASC 470-20, Debt with Conversion and Other Options. Under this guidance, if debt or stock is issued with detachable warrants, the proceeds need to be allocated to the two instruments using either the fair value method, the relative fair value method, or the residual value method. The Company used the relative fair value at the time of issuance to allocate the value received between the convertible note and the warrants.",
            "type": "paragraph"
        },
        {
            "id": 218,
            "context": "The Company estimated the fair value of the Warrants utilizing the Black-Scholes pricing model, which is dependent upon several assumptions such as the expected term of the Warrants, expected volatility of the Company\u2019s stock price over the expected term, expected risk-free interest rate over the expected term and expected dividend yield rate over the expected term. The Company believes this valuation methodology is appropriate for estimating the fair value of warrants. The value allocated to the relative fair value of the Warrants was recorded as debt issuance costs and additional paid in capital.",
            "type": "paragraph"
        },
        {
            "id": 219,
            "context": "The principal, net of the original issue discount and debt issuance costs, including the allocated relative fair value of the Warrants, which are being recognized over the life of the $ 440,000 Note, along with associated interest, is recorded with current liabilities on the Company\u2019s consolidated balance sheets. As of December 31, 2023, the $ 440,000 Note had $ 31,764 of accrued interest, total unamortized debt issuance costs of $ 0 , including the Warrant value and the discount. As of December 31, 2022, the $ 440,000 Note had $ 9,764 of accrued interest, total unamortized debt issuance costs of $ 61,836 , including the Warrant value, and the remaining discount of $ 22,247 .",
            "type": "paragraph"
        },
        {
            "id": 220,
            "context": "Note 8. Preferred Stock\nIssuance of Series A Preferred Stock The shares of Series A Preferred Stock have a stated value of $ 0.25 per share and are initially convertible into shares of common stock at a price of $ 0.05 per share (subject to adjustment upon the occurrence of certain events). The Series A Preferred Stock does not accrue dividends and ranks prior to the common stock upon a liquidation of the Company. The Series A Preferred Stock votes on all matters brought before the shareholders together with the Common stock as a single class and each share of Series A Preferred Stock has a number of votes, initially 5, equal to the number of shares of preferred stock into which it is convertible as of the record date for any vote.",
            "type": "paragraph"
        },
        {
            "id": 221,
            "context": "Issuance of Series A-2 Preferred Stock The shares of Series A-2 Preferred Stock have a stated value of $ 0.16 per share and are convertible into shares of common stock at a price of $ 0.16 per share (subject to adjustment upon the occurrence of certain events). The rights of holders of the Company\u2019s common stock with respect to the payment of dividends and upon liquidation are junior in right of payment to holders of the Series A-2 Convertible Preferred Shares. The rights of the holders of the Company\u2019s Series A-2 Preferred Shares are pari passu to the rights of the holders of the Company\u2019s Series A Preferred Shares currently outstanding.",
            "type": "paragraph"
        },
        {
            "id": 222,
            "context": "Holders of the Series A-2 Convertible Preferred Stock will vote on an as converted basis with the holders of the Company\u2019s common stock and Series A Preferred Shares as to all matters to be voted on by the holders of the common stock. Each Series A-2 Preferred Share shall be entitled to a number of votes equal to five times the number of shares of common stock into which it is then convertible on the applicable record date.",
            "type": "paragraph"
        },
        {
            "id": 223,
            "context": "Note 9. Loss Per Common Share The Company calculates net loss per common share in accordance with ASC 260, Earnings Per Share. Basic and diluted net loss per common share were determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company\u2019s potentially dilutive shares, which include outstanding common stock options, common stock warrants, and convertible debt have not been included in the computation of diluted net loss per share for the years ended December 31, 2023 and 2022 as the result would be anti-dilutive.",
            "type": "paragraph"
        },
        {
            "id": 224,
            "context": "Schedule of Anti-dilutive Securities Excluded from Calculation of Earning Per Share\n\n| 2023 | 2022 |\n| Years Ended December 31, |\n| 2023 | 2022 |\n| Stock options | 1,100,000 | 1,100,000 |\n| Stock warrants | 1,494,854 | 1,576,647 |\n| Total shares excluded from calculation | 2,594,854 | 2,676,647 |\n| Antidilutive securities | 2,594,854 | 2,676,647 |",
            "type": "table"
        },
        {
            "id": 225,
            "context": "Note 10. Stock-based Compensation During the years ended December 31, 2023 and 2022, there was $ 6,000 and $ 30,084 , respectively, in stock-based compensation associated with stock options included in research and development expense. Additionally, during the same periods there was $ 0 and $ 6,968 , respectively, of expense associated with shares issued for services recorded in General and administrative expense.",
            "type": "paragraph"
        },
        {
            "id": 226,
            "context": "There were no options granted during the years ended December 31, 2023 and 2022. There were no options exercised, forfeited or cancelled during either period. As of December 31, 2023, all compensation related to the 1,100,000 outstanding options has been recognized. As of December 31, 2022, there was $ 6,000 of unrecognized compensation related to the 1,100,000 outstanding options which was recognized over a weighted-average period of 3 months. The options were expensed over the vesting period for each Advisor.",
            "type": "paragraph"
        },
        {
            "id": 227,
            "context": "Options outstanding at December 31, 2023 consist of:\nSchedule of Options Outstanding and Exercisable\n\n| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date |\n| March 12, 2020 | 500,000 | 500,000 | $ | 0.40 | March 12, 2025 |\n| June 27, 2020 | 150,000 | 150,000 | $ | 0.40 | June 27, 2025 |\n| January 1, 2021 | 450,000 | 450,000 | $ | 0.65 | December 31, 2025 |\n| Total | 1,100,000 | 1,100,000 |",
            "type": "table"
        },
        {
            "id": 228,
            "context": "Warrants outstanding at December 31, 2023 consist of:\nSchedule of Warrants Outstanding and Exercisable\n\n| Date Issued | Number Outstanding | Number Exercisable | Exercise Price | Expiration Date |\n| August 10, 2021 | 930,000 | 930,000 | $ | 1.25 | August 9, 2024 |\n| February 23, 2022 | 14,854 | 14,854 | $ | 0.705 | February 22, 2024 |\n| July 19, 2022 | 550,000 | 550,000 | $ | 0.50 | July 18, 2025 |\n| Total | 1,494,854 | 1,494,854 |",
            "type": "table"
        },
        {
            "id": 229,
            "context": "Note 11. Related-Party Transactions Due to Related Parties: Amounts due to related parties consist of cash advances received from our majority shareholder, bear no interest and are due on demand. As of December 31, 2023 and 2022 amounts due to related-parties totaled $ 3,236 and $0, respectively and are included in other current liabilities on the Company\u2019s consolidated balance sheets.",
            "type": "paragraph"
        },
        {
            "id": 230,
            "context": "Convertible notes payable, related party: See Note 7.\nNote 12. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes, which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. Given its history of net operating losses, the Company has determined that it is more likely than not that it will not be able to realize the tax benefit of its net operating loss carryforwards. Accordingly, the Company has not recognized a deferred tax asset for this benefit.",
            "type": "paragraph"
        },
        {
            "id": 231,
            "context": "The valuation allowance at December 31, 2023 and 2022 was $ 836,484 and $ 738,128 , respectively. The net change in valuation allowance during the years ended December 31, 2023 and 2022 were $ 98,356 and $ 209,160 , respectively. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. That realization is dependent upon the future generation of taxable income during the period in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred income tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on these considerations, the Company has determined that enough uncertainty exists regarding the realization of the deferred tax asset balance to apply a full valuation allowance against these assets as of December 31, 2023 and 2022. All tax years remain open for examination by taxing authorities.",
            "type": "paragraph"
        },
        {
            "id": 232,
            "context": "Reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for 2023 and 2022 are as follows:\nSchedule of Effective Income Tax Reconcillation\n\n| 2023 | 2022 |\n| For the Years Ended |\n| December 31, |\n| 2023 | 2022 |\n| Income tax at federal statutory rate | 21.00 | % | 21.00 | % |\n| Valuation allowance | ( 21.00 | )% | ( 21.00 | )% |\n| Income tax expense | \u2014 | \u2014 |",
            "type": "table"
        },
        {
            "id": 233,
            "context": "The Company has net operating losses of $ 3,983,258 which begin to expire in 2027 . Future utilization of currently generated federal and state NOL and tax credit carry forwards may be subject to a substantial annual limitation due to the ownership change limitations. The annual limitation may result in the expiration of NOL and tax credit carry-forwards before full utilization.",
            "type": "paragraph"
        },
        {
            "id": 234,
            "context": "Note 13. Commitments and Contingencies\nThere are no pending or threatened legal proceedings as of December 31, 2023. The Company has no non-cancellable operating leases.\nNote 14. Subsequent Event On March 4, 2024, Mercer Street Global Opportunity Fund, LLC, converted $ 10,500 of the principal amount of the $ 806,000 Secured Convertible Promissory Note issued August 10, 2021, into 420,000 shares of the Company\u2019s common stock at a price of $ 0.025 per share.",
            "type": "paragraph"
        },
        {
            "id": 235,
            "context": "",
            "type": "paragraph"
        }
    ],
    "html_tables": [
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Value Based.</b> The Company provides tools that enhance health care for patients while lowering costs to insurance providers and corporate America and allowing physicians to increase their practice revenues.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Patient Centered.</b> Our products streamline the relationship between physicians and their patients, providing a high quality experience for patients, and increasing the value provided to them during care.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Time Saving.</b> Physicians can maximize face-to-face office visits and non-face-to-face patient education while generating additional revenue through reimbursable preventative services.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Prevention Focused.</b> Our products are designed to promote prevention, early detection, management, and reversal of chronic diseases.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"width: 1in\">\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Conducts a comprehensive assessment of patient behaviors, lifestyle and disease risk;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Integrates into existing physician and healthcare interventions;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Collects and compiles relevant, empirical data;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Utilizes this information for decision making; </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Accounts for individual differences yet is appropriate for whole populations;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Provides guidelines for consistent decisions;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Demonstrates flexibility by allowing new variables to be added;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Requires relatively low-skilled IT involvement in assessment or patient program development; and</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td>\u00a0</td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Maximizes revenue by providing less costly \u2018digital\u2019 alternatives to face-to-face interactions.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 25%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Growing Recuring Revenue Base </b></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 5%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Increasing the number of medical practitioners utilizing our point-of-care and digital medicine services, growing our revenue per client metric.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Future distribution channels include Management Service Organization (MSO) partnerships, Independent Physician Associations (IPA\u2019s), and complementary digital health networks.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Expanding Product Portfolio </b></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Additional point-of-care diagnostic, digital medicine, and treatments that PCPs can use, prescribe, and be reimbursed for under existing government and private insurance programs.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Increasing Industry Visibility </b></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Increasing the number of company/university-sponsored medical conferences partnering with various Universities to introduce and educate members of the medical community about the technology and revenue opportunities available.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the federal physician self-referral law, commonly referred to as the Stark Law;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the federal Anti-Kickback Act;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the criminal healthcare fraud provisions of HIPAA;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the federal False Claims Act;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">reassignment of payment rules that prohibit certain types of billing and collection by companies which do business with PCPs;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">similar state law provisions pertaining to anti-kickback, self-referral and false claims issues;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">state laws that prohibit general business corporations, such as us, from practicing medicine; and</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">laws that regulate debt collection practices as applied to our debt collection practices.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the federal physician self-referral law, commonly referred to as the Stark Law;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the federal Anti-Kickback Act;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the criminal healthcare fraud provisions of HIPAA;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the federal False Claims Act;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">reassignment of payment rules that prohibit certain types of billing and collection;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">similar state law provisions pertaining to anti-kickback, self-referral and false claims issues;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">state laws that prohibit general business corporations, such as us, from practicing medicine; and</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">laws that regulate debt collection practices as applied to our debt collection practices.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.5in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf government or private initiatives that affect the manner in which healthcare providers interact with patients, payers or other healthcare industry participants, including changes in pricing or means of delivery of healthcare products and services; </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf consolidation of healthcare industry participants; </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf reductions in governmental funding for healthcare; </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cfadverse changes in business or economic conditions affecting healthcare payers or providers, pharmaceutical, biotechnology or medical device companies or other healthcare industry participants; and</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf restructuring of the healthcare industry and possible elimination of private insurers. </span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">actual or anticipated fluctuations in our operating results;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the limited number of securities analysts covering us and distributing research and recommendations about us;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the low public float for our common stock;</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">the low trading volume of our common stock;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">announcements concerning our business or those of our competitors;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">actual or perceived limitations on our ability to raise capital when we require it, and to raise such capital on favorable terms;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">conditions or trends in our industry;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">litigation;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">changes in market valuations of similar companies;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">future sales of common stock;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">departure of key personnel or failure to hire key personnel; and</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">general market conditions.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Price Range</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"border-bottom: Black 1.5pt solid; text-align: center\">Period</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">High</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Low</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-style: italic\">Year Ended December 31, 2023:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 68%; text-align: left; padding-left: 10pt\">First Quarter</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 12%; text-align: right\">0.398</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 12%; text-align: right\">0.11</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Second Quarter</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.247</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.065</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Third Quarter</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.198</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.0315</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Fourth Quarter</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.09</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.016</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-style: italic\">Year Ended December 31, 2022:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">First Quarter</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.75</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.30</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Second Quarter</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.58</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.30</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Third Quarter</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.40</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.12</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Fourth Quarter</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.18</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">0.12</td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"font-weight: bold; text-align: center\">For the Years Ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31,</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 64%; text-align: left\">Allergy Diagnostic Kit Sales</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">666,600</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\">685,062</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Immunotherapy Treatment Sales</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">363,184</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">484,411</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Subscription Revenue</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">72,200</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">18,654</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Integrated Service Program Revenue</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">270,022</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">8,137</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Training &amp; Other Revenue</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">4,650</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">11,288</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Shipping and handling</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">32,339</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">35,634</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Total revenue</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">1,408,995</td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">1,243,186</td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: white\"> <td style=\"border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Name</b></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 2%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Age</b></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 2%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Title</b></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Troy Grogan</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">46</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">CEO, CFO and Chairman</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"border-bottom: Black 1.5pt solid; text-align: center\">Name of Shareholder</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">Amount and <br/> Nature of Beneficial</p> <p style=\"margin-top: 0; margin-bottom: 0\">Ownership</p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Percent of<br/> Common Stock</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"font-weight: bold; text-align: left\">Directors and Executive Officers:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 60%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Troy Grogan<sup>1</sup></span></td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 16%; text-align: right\">11,397,209</td><td style=\"width: 1%; text-align: left\">(1)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 16%; text-align: right\">52.98</td><td style=\"width: 1%; text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">All directors and executive officers as a group (1 person)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">11,397,209</td><td style=\"text-align: left\">(1)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">52.98</td><td style=\"text-align: left\">%</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\"><b>Owners of more than 5% of our outstanding shares:</b></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b></b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Mercer Street Global Opportunity Fund, LLC</span></p></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">7,659,694</td><td style=\"text-align: left\">(2)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">46.18</td><td style=\"text-align: left\">%</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"text-align: center\">Year Ended</td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"text-align: center\">Year Ended</td><td>\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, 2022</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; text-align: left\">Audit fees</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\">64,500</td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\">55,000</td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Exhibit</b></span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>No.</b></span></p></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.1in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><b>Description</b></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">3.1</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315221014750/formdef14c.htm\" style=\"-sec-extract: exhibit\">Articles of Incorporation (incorporated herein by reference to Exhibit B to the Information Statement on Form 14-C filed June 21, 2021).</a> </span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">3.2</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315222010296/ex3-1.htm\" style=\"-sec-extract: exhibit\">Certificate of Amendment to Certificate of Incorporation to effect Name Change (incorporated herein by reference to Exhibit 3.01 to the Registrant\u2019s Current Report on Form 8-K filed on April 19, 2022).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">3.3</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315221014750/formdef14c.htm\" style=\"-sec-extract: exhibit\">By-Laws (incorporated herein by reference to Exhibit C to the Information Statement on Form 14-C filed June 21, 2021).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">4.1</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315219013708/ex3-1.htm\" style=\"-sec-extract: exhibit\">Certificate of Designation authorizing issuance of Series A Preferred Stock (incorporated herein by reference to Exhibit 3.01 to the Registrant\u2019s Current Report on Form 8-K filed on September 5, 2019).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">4.2</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315221032849/ex3-1.htm\" style=\"-sec-extract: exhibit\">Certificate of Designation authorizing the issuance of the Series A-2 Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Report on Form 8-K filed December 30, 2021).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">10.1</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315222020769/ex10-1.htm\" style=\"-sec-extract: exhibit\">Securities Purchase Agreement between QHSLab, Inc. and Mercer Street Global Opportunity Fund, LLC dated July 21, 2022 (incorporated herein by reference to Exhibit 10.1 to the Report on Form 8-K filed July 29, 2022).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">10.2</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315220003708/ex10-1.htm\" style=\"-sec-extract: exhibit\">2020 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Company\u2019s Registration Statement on Form S-8 filed March 11, 2020).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">10.3</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315222020769/ex10-3.htm\" style=\"-sec-extract: exhibit\">Common Stock Purchase Warrant to purchase 550,000 shares issued by QHSLab, Inc. to Mercer Street Global Opportunity Fund, LLC dated July 21, 2022 (incorporated herein by reference to Exhibit 10.3 to the Report on Form 8-K filed July 29, 2022).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">10.4</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315222020769/ex10-4.htm\" style=\"-sec-extract: exhibit\">Registration Rights Agreement in favor of Mercer Street Global Opportunity Fund, LLC (incorporated herein by reference to Exhibit 10.4 to the Report on Form 8-K filed July 29, 2022).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">14.1</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315221005816/ex14-1.htm\" style=\"-sec-extract: exhibit\">Code of Business Conduct and Ethics (incorporated herein by reference to Exhibit 14.1 to the Company\u2019s Report on Form 10-K filed on March 11, 2021).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">19.2</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315224011551/ex19-2.htm\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Insider Trading Policy </span></a></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">21.1</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315219019583/ex21-1.htm\" style=\"-sec-extract: exhibit\">Subsidiaries (incorporated herein by reference to Exhibit 21.1 to the Registrant\u2019s Current Report on Form 8-K filed on December 23, 2019).</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">31</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315224011551/ex31.htm\">Certification of CEO and CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">32</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"https://www.sec.gov/Archives/edgar/data/856984/000149315224011551/ex32.htm\">Certification of CEO and CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.75in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.SCH</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.1in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Schema Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.CAL</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.DEF</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.LAB</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">101.PRE</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">104</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td colspan=\"2\" style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">QHSLab, Inc.</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 3%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 47%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 50%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">By:</span></td> <td style=\"border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><i>/s/ Troy Grogan</i></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Troy Grogan</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Chief Executive Officer, Chief Financial Officer</span></p> <p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0pt 0\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">And Director</span></p></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"#nja_001\">Report of Independent Registered Public Accounting Firm</a></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">F-2</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><a href=\"#nja_002\">Consolidated Balance Sheets as of December 31, 2023 and 2022</a></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">F-4</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><a href=\"#nja_003\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Consolidated Statements of Operations for the Years Ended December 31, 2023 and 2022</span></a></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">F-5</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><a href=\"#nja_004\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Consolidated Statements of Stockholders\u2019 (Deficit) Equity for the Years Ended December 31, 2023 and 2022</span></a></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">F-6</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><a href=\"#nja_005\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Consolidated Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">F-7</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; background-color: white\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><a href=\"#nja_006\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Notes to Consolidated Financial Statements</span></a></td> <td style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">F-8</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 24px\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 24px\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">We obtained the impairment analysis, reviewed, and determined if the Company assessed the intangible assets at the appropriate level.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 24px\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 24px\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">We reviewed the qualitative factors analyzed by the Company and performed an assessment of any possible indicators of impairment.</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 24px\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 24px\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u25cf</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">We obtained the computation of the sum of undiscounted cash flows expected to result from the asset group and reviewed the analysis as to whether the carrying amount of the asset group is recoverable.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><p style=\"font: 10pt Times New Roman, Times, Serif; margin: 0\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">/s/ <span id=\"xdx_90C_edei--AuditorName_c20230101__20231231_zZam5ptyhgwl\"> Accell Audit &amp; Compliance, P.A. </span></span></p></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 50%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">We have served as the Company\u2019s auditor since 2021.</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 50%\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">PCAOB Firm ID#<span id=\"xdx_900_edei--AuditorFirmId_c20230101__20231231_za5R1EU5cvZe\"> 3289 </span></span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span id=\"xdx_901_edei--AuditorLocation_c20230101__20231231_zPLBtlc6cA8f\" style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"> Tampa, Florida </span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">March 27, 2024</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_30B_111_znyXTJQNqJK1\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Consolidated Balance Sheets\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_496_20231231_zx4uJfpgHNWa\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49D_20221231_zC0sEMgLRQcf\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, 2022</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\">\u00a0</td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"text-align: right\">\u00a0</td><td>\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--AssetsAbstract_iB_zr8nmp46u1i9\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: center\">Assets</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--AssetsCurrentAbstract_i01B_zSZuzXddSwO7\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Current Assets:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzpfp_zby5Zvrd6chi\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; text-align: left; padding-left: 10pt\">Cash and cash equivalents</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 51,582 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 178,694 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzpfp_zoDmLJPglUF5\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Accounts receivable, net</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 71,382 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 47,734 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--InventoryNet_i02I_maCzpfp_zaUYBUiA69xj\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt\">Inventory</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 25,181 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 51,840 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--OtherPrepaidExpenseCurrent_i02I_maCzpfp_zX00a6ieYu5g\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Prepaid expenses and other current assets</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 7,987 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 7,310 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--AssetsCurrent_i02TI_mtCzpfp_maCzEmA_zPLglLHEg7D7\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 20pt\">Total current assets</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 156,132 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 285,578 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--AssetsNoncurrentAbstract_i01B_zPTEBwG3SsKf\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Non-current assets:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--CapitalizedSoftwareDevelopmentCostsForSoftwareSoldToCustomers_i02I_maCzEmA_zLiOzu04a6Fg\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Capitalized software development costs, net</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 93,079 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 167,543 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_maCzEmA_z09AXIbfMxid\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Intangible assets, net</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,432,221 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,504,332 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--Assets_i01TI_mtCzEmA_zrQaX0Ox0oIk\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Total assets</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,681,432 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,957,453 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z5OZ0ulOzHz6\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: center\">Liabilities and Stockholders\u2019 (Deficit) Equity</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zvAGlG0njw34\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Current Liabilities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--AccountsPayableCurrent_i02I_maCzS3F_zInbSHjqE4Ce\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Accounts payable</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 78,907 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 85,743 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzS3F_zQ3AHwyVcZ6c\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Other current liabilities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 196,590 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 116,774 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--ShortTermBorrowings_i02I_maCzS3F_zdSUJg54dSra\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Loans payable, current portion</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 546,052 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 342,391 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maCzS3F_zsN46qIJMa81\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Convertible notes payable</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,235,500 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,161,918 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--LiabilitiesCurrent_i02TI_mtCzS3F_maCzjGS_zpwsMIHH5yZi\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 20pt\">Total current liabilities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,057,049 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,706,826 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zcAIqjH4JR44\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Non-current liabilities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--LongTermLoansPayable_i02I_maCzGRM_zTCgwOprdIt\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 1.5pt; text-align: left; padding-left: 10pt\">Loans payable, non-current portion</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0104\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 174,382 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--LiabilitiesNoncurrent_i02TI_mtCzGRM_maCzjGS_zhtFbahoYNJ7\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Total non-current liabilities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0107\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 174,382 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--Liabilities_i01TI_mtCzjGS_maLASEzOfw_zaWipfwtGtYl\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Total liabilities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,057,049 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,881,208 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzOfw_zcZSZNJCnKwe\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Commitments and contingencies (Note 13)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--StockholdersEquityAbstract_i01B_zN6iZHQ3nH4l\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Stockholders\u2019 (Deficit) Equity:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Preferred stock, <span id=\"xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20231231_zSpMwtDIHD62\" title=\"Preferred stock, shares authorized\"><span id=\"xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20221231_zaA0ZO2odCOl\" title=\"Preferred stock, shares authorized\">  10,000,000  </span></span> shares authorized</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_maSEzH7R_zlbFWEbJTdI9\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Preferred stock Series A, $<span id=\"xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zosq2qTNZ0Tc\" title=\"Preferred stock, par value\"><span id=\"xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2FiHUVLy2cj\" title=\"Preferred stock, par value\">  0.0001  </span></span> par value; <span id=\"xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zacsVUtD1U91\" title=\"Preferred stock, shares issued\"><span id=\"xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zRU8tpxVKzG6\" title=\"Preferred stock, shares issued\"><span id=\"xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zLh3TbP77X3b\" title=\"Preferred stock, shares outstanding\"><span id=\"xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zHcvlH6kKEM1\" title=\"Preferred stock, shares outstanding\">    1,080,092    </span></span></span></span> shares issued and outstanding</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 108 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 108 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_maSEzH7R_zVvvydJ3xWPb\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Preferred stock Series A-2, $<span id=\"xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zdNdGXIrHajc\" title=\"Preferred stock, par value\"><span id=\"xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_ztak8g1QDBBb\" title=\"Preferred stock, par value\">  0.0001  </span></span> par value; <span id=\"xdx_901_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zRzzdbcgcS4c\" title=\"Preferred stock, shares issued\"><span id=\"xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zKfC6ou0w2pd\" title=\"Preferred stock, shares issued\"><span id=\"xdx_906_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zZ2w6Hju5PCh\" title=\"Preferred stock, shares outstanding\"><span id=\"xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zbCk2hfnQGqc\" title=\"Preferred stock, shares outstanding\">    2,644,424    </span></span></span></span> shares issued and outstanding</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 264 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 264 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_maSEzH7R_zisWTRQ5bslh\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Preferred stock</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 264 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 264 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--CommonStockValue_i02I_maSEzH7R_zjRopG2FONT7\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Common stock, <span id=\"xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20221231_z3R4IWmmyiu9\"> 900,000,000  </span>shares authorized, $<span id=\"xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20221231_zhdxNVT0dznf\"> 0.0001 </span> par value; <span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_903_eus-gaap--CommonStockSharesIssued_iI_c20231231_zMHpfV2roxHd\" title=\"Common stock, shares issued\"><span id=\"xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_zA2QXbxPyCX7\" title=\"Common stock, shares outstanding\">  9,735,508  </span></span> and </span> <span id=\"xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20221231_zUosoXlKYV2j\"><span id=\"xdx_903_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zwbwKwi1EhVh\" title=\"Common stock, shares outstanding\">  9,315,508  </span> </span>shares issued and outstanding at December 31, 2023 and 2022, respectively</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 974 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 932 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--AdditionalPaidInCapital_i02I_maSEzH7R_zHieTHWD6Lgl\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Additional paid-in capital</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,606,295 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,589,837 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzH7R_zl72x0V4Ilfa\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Accumulated deficit</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 3,983,258 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 3,514,896 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_406_eus-gaap--StockholdersEquity_i02TI_pp0p0_maLASEzOfw_mtSEzH7R_zDGB4Dtq9iyh\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 20pt\">Total stockholders\u2019 (deficit) equity</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 375,617 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 76,245 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzOfw_zcI7LENTKhn8\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt; padding-left: 30pt\">Total liabilities and stockholders\u2019 (deficit) equity</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,681,432 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 1,957,453 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_30B_113_z9l5fVqHHU0e\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Consolidated Statements of Operations\"> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_490_20230101__20231231_zSLkXmsS03vc\" style=\"text-align: center\">Year Ended</td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_49C_20220101__20221231_zCbDAwPOzNtj\" style=\"text-align: center\">Year Ended</td><td>\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, 2022</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"text-align: right\">\u00a0</td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" style=\"text-align: right\">\u00a0</td><td>\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzsrL_z50GFFX0olak\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%\">Revenue</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 1,408,995 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 1,243,186 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--CostOfRevenue_msGPzsrL_zQgoDoKKrD73\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt\">Cost of revenue</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 615,388 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 623,667 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--GrossProfit_iT_maCz015_mtGPzsrL_zJOtciCT6d12\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Gross profit</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 793,607 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 619,519 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zM2YtOnrYTn4\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Operating Expenses:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_400_eus-gaap--SellingAndMarketingExpense_i01_maOEzQnC_zlhOf2Wgy5db\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Sales and marketing</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 488,537 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 530,317 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzQnC_zjGHkai1SIQb\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">General and administrative</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 259,108 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 387,512 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzQnC_zSsANbAkKYzf\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Research and development</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 214,008 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 190,117 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--DepreciationAndAmortization_i01_maOEzQnC_zBcJnlzhFOj7\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; padding-left: 10pt\">Amortization</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 72,112 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 72,112 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--OperatingExpenses_i01T_msCz015_mtOEzQnC_zfJQADxF72Hj\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Total Operating Expenses</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,033,765 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,180,058 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--OperatingIncomeLoss_iT_mtCz015_maILFCOzs36_zt3yk1A6YbO1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Net operating loss</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 240,158 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 560,539 </td><td style=\"text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_z8LxZP5qFO3k\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Other income (expense)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--InterestExpense_i01N_di_msILFCOzs36_zsxS45ugC9Kl\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Interest expense</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 230,494 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 433,442 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_406_eus-gaap--OtherIncome_i01_maILFCOzs36_zWeQ0EpPIDLe\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Other income</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,290 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0217\">-</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_pp0p0_maILFCOzs36_z0rb0KVNaYT5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Loss on extinguishment of debt</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0219\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 2,020 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_40D_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pp0p0_mtILFCOzs36_maNILzQON_zMuL4GDzQ1vg\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Loss before income taxes</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 468,362 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 996,001 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_403_eus-gaap--IncomeTaxExpenseBenefit_i01_pp0p0_msNILzQON_z1Bdd8DnZlQ5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Provision on income taxes</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0225\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0226\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--NetIncomeLoss_iT_mtNILzQON_zStzv9VOAzxa\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Net loss</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 468,362 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\">( 996,001 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Basic and diluted net loss per share</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_\" id=\"xdx_902_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zJL1y4QvhfI1\" title=\"Basic net loss per share\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_\" id=\"xdx_901_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_zazT2Ux7zkS5\" title=\"Diluted net loss per share\">(  0.05  </span></span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_\" id=\"xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zfVMMNw7Pykc\" title=\"Basic net loss per share\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_\" id=\"xdx_90D_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_z4m6s16rznm5\" title=\"Diluted net loss per share\">(  0.11  </span></span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-bottom: 2.5pt\">Weighted average shares outstanding (basic and diluted)</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_\" id=\"xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_z8MY0h0DGmKc\" title=\"Weighted average shares outstanding: (Basic)\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_\" id=\"xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zc405zVB5oJ3\" title=\"Weighted average shares outstanding: (Diluted)\">  9,416,768  </span></span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_\" id=\"xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_z3aekYllR2\" title=\"Weighted average shares outstanding: (Diluted)\"><span class=\"xdx_phnt_U3RhdGVtZW50IC0gQ29uc29saWRhdGVkIFN0YXRlbWVudHMgb2YgT3BlcmF0aW9ucwA_\" id=\"xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_znb5VUKShnd5\" title=\"Weighted average shares outstanding: (Basic)\">  8,997,129  </span></span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_30A_114_zHaIisNwSz7k\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Consolidated Statements of Stockholders' (Deficit) Equity\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Shares</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_us-gaap--SeriesAPreferredStockMember_zXbkoM7MbCpc\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Amount</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Shares</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--SeriesATwoPreferredStockMember_zKT4wyHIk4a2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Amount</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Shares</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_z2T1fDTu5kw\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Amount</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4BE_us-gaap--StatementEquityComponentsAxis_custom--UnearnedStockCompensationMember_zfhJc2NxjMBl\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Compensation</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zzmYSYArz9w5\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Capital</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z0Cm4wwvALq2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Deficit</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_4B1_zp13jsSGHX8c\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">(Deficit)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">Preferred \u2013</p> <p style=\"margin-top: 0; margin-bottom: 0\">Stock- Series A</p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">Preferred</p> <p style=\"margin-top: 0; margin-bottom: 0\">Stock - Series A-2</p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Common Stock</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"padding-bottom: 1.5pt; text-align: center\">Unearned Stock</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"padding-bottom: 1.5pt; text-align: center\"><p style=\"margin-top: 0; margin-bottom: 0\">Additional</p> <p style=\"margin-top: 0; margin-bottom: 0\">Paid-In</p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"padding-bottom: 1.5pt; text-align: center\">Accumulated</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"padding-bottom: 1.5pt; text-align: center\">Total <br/> Stockholders\u2019 (<span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Deficit) </span></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Shares</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Amount</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Shares</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Amount</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Shares</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Amount</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Compensation</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Capital</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Deficit</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Equity</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr id=\"xdx_431_c20220101__20221231_eus-gaap--StockholdersEquity_iS_z5SW4VO8m7lh\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 40%\">Balance at January 1, 2022</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zDTqJHy9dIC6\" style=\"width: 3%; text-align: right\" title=\"Balance, shares\"> 1,080,092 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 3%; text-align: right\"> 108 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_z73ee4EedSDl\" style=\"width: 3%; text-align: right\" title=\"Balance, shares\"> 2,644,424 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 3%; text-align: right\"> 264 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxSh7LgWPGYh\" style=\"width: 3%; text-align: right\" title=\"Balance, shares\"> 8,756,093 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 3%; text-align: right\"> 876 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 3%; text-align: right\">( 6,968 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 3%; text-align: right\"> 3,348,681 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 3%; text-align: right\">( 2,518,895 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 1%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 3%; text-align: right\"> 824,066 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_ecustom--WarrantsIssuedAsDeferredFinancingCosts_zFuulFPwkPB3\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Warrants issued as deferred financing costs</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0261\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0262\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0263\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0264\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 81,183 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0266\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 81,183 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zc7gNIaU95e8\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Shares issued for services</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0269\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0270\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0271\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 6,968 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0273\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0274\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 6,968 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zTaX4kblOGg3\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Conversion of notes payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0277\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0278\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWn05v6Ieu5i\" style=\"text-align: right\" title=\"Conversion of notes payable, shares\"> 309,415 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 31 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0280\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 77,894 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0282\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 77,925 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zNO7O9QrcBZc\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Warrants issued with conversion of notes payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0287\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0288\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0289\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0290\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,020 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0292\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,020 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zDF2MMHWZYfl\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Stock-based compensation expense</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0295\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0296\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0297\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0298\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 30,084 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0300\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 30,084 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--StockRepurchasedDuringPeriodValue_zWi2B0Mym5Sl\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 10pt\">Share purchase</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0303\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0304\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaKWwx2afJi3\" style=\"text-align: right\" title=\"Share purchase, shares\"> 250,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 25 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0306\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 49,975 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0308\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 50,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--NetIncomeLoss_zI7Df8iPysac\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Net loss</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">-</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0313\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">-</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0314\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">-</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0315\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0316\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0317\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 996,001 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 996,001 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_430_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zDJoOGgdZTv1\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Balance at December 31, 2022</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zX6yTGjV8dJ3\" style=\"text-align: right\" title=\"Balance, shares\"> 1,080,092 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 108 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_980_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zGz48iN2btZk\" style=\"text-align: right\" title=\"Balance, shares\"> 2,644,424 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 264 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwB5m3nDrVok\" style=\"text-align: right\" title=\"Balance, shares\"> 9,315,508 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 932 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0324\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 3,589,837 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">( 3,514,896 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 76,245 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_435_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zvfcWXhB2rcf\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>Balance</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zzG5tO1egSn8\" style=\"text-align: right\" title=\"Balance, shares\"> 1,080,092 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 108 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_z1WnACb8xCBf\" style=\"text-align: right\" title=\"Balance, shares\"> 2,644,424 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 264 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfUwc4OlEftc\" style=\"text-align: right\" title=\"Balance, shares\"> 9,315,508 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 932 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0338\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 3,589,837 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\">( 3,514,896 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 76,245 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_zdn8pxtl8LJi\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Stock-based compensation expense</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0349\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0350\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0351\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0352\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 6,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0354\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 6,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zGI8wFTxEOHi\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Conversion of notes payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0357\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">-</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0358\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_982_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFSC1L6Z3d1c\" style=\"text-align: right\" title=\"Conversion of notes payable, shares\"> 420,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 42 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0360\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,458 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0362\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,500 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--NetIncomeLoss_zkvyKj4IrDf8\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Net loss</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">-</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0367\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">-</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0368\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">-</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0369\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0370\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0371\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 468,362 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 468,362 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_431_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zTjWXi6kmVff\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt\">Balance at December 31, 2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zJSrJFWf9yv6\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"> 1,080,092 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 108 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zr7QwhGcljD\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"> 2,644,424 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 264 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98C_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zInEKj3ehvHg\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"> 9,735,508 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 974 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0378\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 3,606,295 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 3,983,258 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 375,617 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_431_c20230101__20231231_eus-gaap--StockholdersEquity_iE_zA5AM076g6v8\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt\">Balance </td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_ziFXRfCNGRue\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"> 1,080,092 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 108 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_982_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--SeriesATwoPreferredStockMember_zIgA2GKQicP5\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"> 2,644,424 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 264 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_987_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKLKB1MtVaEc\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Balance, shares\"> 9,735,508 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 974 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0392\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 3,606,295 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 3,983,258 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 375,617 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" id=\"xdx_301_112_zDO1Z7tLA1mi\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\" summary=\"xdx: Statement - Consolidated Statements of Cash Flows\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_49A_20230101__20231231_zxdDUVUXVVe3\" style=\"text-align: center\">Year Ended</td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\" id=\"xdx_49C_20220101__20221231_zgCt1DEuUdM8\" style=\"text-align: center\">Year Ended</td><td>\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, 2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, 2022</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td colspan=\"2\">\u00a0</td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\">\u00a0</td><td>\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zytbiubB3Rti\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Operating activities</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_409_eus-gaap--NetIncomeLoss_i01_maNCPBUz3a7_zfh6YVnrJtU2\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"width: 60%; text-align: left; padding-left: 10pt\">Net loss</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\">( 468,362 </td><td style=\"width: 1%; text-align: left\">)</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\">( 996,001 </td><td style=\"width: 1%; text-align: left\">)</td></tr> <tr id=\"xdx_405_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zGaIEvKGQkc4\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Adjustments to reconcile net loss to net cash from operating activities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--ProvisionForDoubtfulAccounts_i02_maNCPBUz3a7_z72Qb4pD62b1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 20pt\">Allowance for doubtful accounts</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 10,216 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 8,230 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUz3a7_zQiIFmXl46J1\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-left: 20pt\">Amortization</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 146,575 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 127,959 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--AmortizationOfFinancingCosts_i02_maNCPBUz3a7_zYLGc9GdZA71\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 20pt\">Amortization of debt and warrant issuance costs</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 84,082 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 305,996 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--ShareBasedCompensation_i02_maNCPBUz3a7_zwK266D9HhD2\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 20pt\">Stock-based compensation</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 6,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 30,084 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--IssuanceOfStockAndWarrantsForServicesOrClaims_i02_maNCPBUz3a7_zGF3acryGbp6\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 20pt\">Shares issued for services</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0424\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 6,968 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUz3a7_z2vaJBukuZMe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 20pt\">Loss on extinguishment of debt</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0427\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 2,020 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zlIXLQIOjYu6\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 20pt\">Changes in operating assets and liabilities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msNCPBUz3a7_znDWHy4r9LZ3\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 30pt\">Accounts receivable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 33,864 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 14,510 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--IncreaseDecreaseInInventories_i03N_di_msNCPBUz3a7_zaWItPpjzKf7\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"padding-left: 30pt\">Inventory</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 26,659 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 13,900 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUz3a7_zsrRjKsJS4Ma\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 30pt\">Prepaid expenses and other current assets</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 677 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 15,403 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUz3a7_zPqRabxaJX57\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 30pt\">Accounts payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 6,836 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 65,374 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i03_maNCPBUz3a7_zngTOQtkE5m6\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt; text-align: left; padding-left: 30pt\">Other current liabilities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 76,580 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 54,563 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtNCPBUz3a7_maCCERCzGUk_zV4seFInDm2k\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 20pt\">Cash flows from operating activities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 159,627 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 350,994 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zw4jBuiqSXzk\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Investing activities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--PaymentsForSoftware_i01N_di_msNCPBUzVEj_zVVzMadVD3Rk\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Capitalized software</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0454\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 37,119 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzVEj_maCCERCzGUk_zuQdUL4a7104\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 20pt\">Cash flows from investing activities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0457\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 37,119 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zPr5qj2AsbPg\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Financing activities:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzm6h_ztr3d3Eqh0p5\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Proceeds from sales of common stock</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0463\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 50,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzm6h_z3BplX3cBa5g\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Issuance of convertible notes payable</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0466\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 400,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40C_eus-gaap--ProceedsFromRelatedPartyDebt_i01_maNCPBUzm6h_zrk16MPhAy1h\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Proceeds from related-party borrowings</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 3,236 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0470\">-</span></td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--ProceedsFromShortTermDebt_i01_maNCPBUzm6h_zNSdVvXLyaDf\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Proceeds of loan borrowings</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 388,700 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 239,800 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--RepaymentsOfShortTermDebt_i01N_di_msNCPBUzm6h_zLg105Redlsh\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Repayments of loan borrowings</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 359,421 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 379,848 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_402_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_msNCPBUzm6h_z5eE865GITN\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Payment of debt issuance costs</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0478\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 30,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_maCCERCzGUk_mtNCPBUzm6h_zjZZg5Ra67Gl\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 20pt\">Cash flows from financing activities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 32,515 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 279,952 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCzGUk_zafwZiKbCQHc\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 20pt\">Change in cash</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 127,112 </td><td style=\"text-align: left\">)</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">( 108,161 </td><td style=\"text-align: left\">)</td></tr> <tr id=\"xdx_40E_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zRrpJorqnupl\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Cash and cash equivalents - beginning of year</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 178,694 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 286,855 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zS9Ca9jb4UT1\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Cash and cash equivalents - end of period</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 51,582 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 178,694 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td>\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zsm9BOQOQBNe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">Supplemental disclosures of cash flow activity:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--InterestPaidNet_i01_zSA6DYRAT768\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt; padding-left: 10pt\">Cash paid for interest</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> 61,295 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"> 71,785 </span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_408_eus-gaap--IncomeTaxesPaidNet_i01_zHd2bziYPmob\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 2.5pt; padding-left: 10pt\">Cash paid for taxes</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0499\">-</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0500\">-</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zWkWz4h9Abr9\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Supplemental noncash investing and financing activity:</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_ecustom--DebtAndAccruedInterestConvertedToSharesOfCommonStock_i01_zS82XM5v2cMi\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-left: 10pt\">Debt and accrued interest converted to shares of common stock</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"> 10,500 </span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 77,925 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_ecustom--WarrantsIssuedInConjunctionWithConvertibleNotePayable_i01_zlQBKObtogi2\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-left: 10pt\">Warrants issued in conjunction with convertible note payable</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0508\">-</span></td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 81,183 </td><td style=\"text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 1.5in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">U.S. Method Patent</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJMOl5w7B4U4\" title=\"Finite-lived intangible assets, amortization method\"> 13.4 </span> years</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Web Domain</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_907_eus-gaap--ImpairedIntangibleAssetDescription_c20230101__20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebDomainMember_zTMJtfjUTg9j\" title=\"Impaired intangible asset\"> Indefinite life </span></span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">Trademark</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\"><span id=\"xdx_904_eus-gaap--ImpairedIntangibleAssetDescription_c20230101__20231231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zMuoxNwbENUl\" title=\"Impaired intangible asset\"> Indefinite life </span></span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse\"> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif; width: 0.5in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(i)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">identify the contract(s) with a customer;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; white-space: nowrap\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(ii)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">identify the performance obligations in the contract(s);</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; white-space: nowrap\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(iii)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">determine the transaction price;</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; white-space: nowrap\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(iv)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">allocate the transaction price to the performance obligations in the contract(s); and</span></td></tr> <tr style=\"font: 10pt Times New Roman, Times, Serif; vertical-align: top\"> <td style=\"font: 10pt Times New Roman, Times, Serif\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">\u00a0</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; white-space: nowrap\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">(v)</span></td> <td style=\"font: 10pt Times New Roman, Times, Serif; text-align: justify\"><span style=\"font-family: Times New Roman, Times, Serif; font-size: 10pt\">recognize revenue when (or as) the Company satisfies a performance obligation.</span></td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49C_20231231_zrfzI7x9wXL4\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, <br/> 2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_492_20221231_ztYfPPOfyrS5\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, <br/> 2022</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--AccountsReceivableGrossCurrent_iI_maARNCzPzS_zc5eoUTr53ik\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; text-align: left\">Accounts receivable</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 89,827 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 16%; text-align: right\"> 55,964 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_di_msARNCzPzS_zJXa055JCjJf\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Allowance for doubtful accounts</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 18,445 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 8,230 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_406_eus-gaap--AccountsReceivableNetCurrent_iTI_mtARNCzPzS_zPJRa0PgJv2k\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Accounts receivable, net</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 71,382 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 47,734 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: center\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: center\">Estimated Useful Life <br/> (in years)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_491_20231231_z9HELthtxiM6\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"text-align: center; margin-top: 0; margin-bottom: 0\">December 31,</p> <p style=\"text-align: center; margin-top: 0; margin-bottom: 0\">2023</p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_494_20221231_zY0ISIeEUcR2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\"><p style=\"text-align: center; margin-top: 0; margin-bottom: 0\">December 31,</p> <p style=\"text-align: center; margin-top: 0; margin-bottom: 0\">2022</p></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--CapitalizedComputerSoftwareGross_iI_maCCSNz2fq_zL7kNXfHeI71\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 48%; text-align: left\">Capitalized software</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 14%; text-align: center\"><span id=\"xdx_909_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zjJ1t1r5iRU1\" title=\"Finite-lived intangible assets, amortization method\"> 3.0 </span></td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"> 223,390 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"> 223,390 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--CapitalizedComputerSoftwareAccumulatedAmortization_iNI_di_msCCSNz2fq_z3n6sHlAGLz1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Accumulated amortization</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 130,311 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 55,847 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_400_eus-gaap--CapitalizedComputerSoftwareNet_iTI_mtCCSNz2fq_zPG8Ql85HMlh\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Capitalized software, net</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 93,079 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 167,543 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--FiniteLivedIntangibleAssetsNetAbstract_iB_zLmohWj1Jm5i\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Intangible Assets:</td><td>\u00a0</td> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\">\u00a0</td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zJZr17B7bV3l\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left\">U.S. Method Patent</td><td>\u00a0</td> <td style=\"text-align: center\"><span id=\"xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtY_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zcIu7s9rTqXh\" title=\"Finite-lived intangible assets, amortization method\"> 13.4 </span></td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 967,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 967,500 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--WebDomainMember_zVJ2UnLOidca\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Web Domain</td><td>\u00a0</td> <td style=\"text-align: center\">N/A</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 161,250 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 161,250 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zspTOVYN1JHf\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt\">Trademark</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: center; padding-bottom: 1.5pt\">N/A</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 483,750 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 483,750 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_402_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzGJu_zEcf33SLBeNj\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Total Intangible assets</td><td>\u00a0</td> <td style=\"text-align: center\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 1,612,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td style=\"text-align: right\"> 1,612,500 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzGJu_zyBsvsYlep7k\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt; padding-left: 10pt\">Accumulated amortization</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 180,279 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 108,168 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtFLIANzGJu_z0QO94UU9oQ2\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Intangible assets, net</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: center; padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,432,221 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">$</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,504,332 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_494_20231231_z6H3hCW07zCk\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, <br/> 2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_491_20221231_zRlq1W5pt9h3\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">December 31, <br/> 2022</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr id=\"xdx_40B_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableOneMember__us-gaap--DebtInstrumentAxis__custom--NoteOneShareholderMember_z4bVwT6G6I82\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 64%; text-align: left\">Note 1 \u2013 Shareholder</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"> 100,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td style=\"width: 14%; text-align: right\"> 100,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_401_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableTwoMember__us-gaap--DebtInstrumentAxis__custom--NoteTwoMercerNoteMember_zz6j22ovHxkh\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left\">Note 2 \u2013 Mercer Note</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 695,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 706,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_406_ecustom--ConvertibleNotesPayableGross_iI_hus-gaap--ShortTermDebtTypeAxis__custom--ConvertibleNotesPayableThreeMember__us-gaap--DebtInstrumentAxis__custom--NoteThreeMercerNoteTwoMember_zYi8pok8ZLae\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Note 3 \u2013 Mercer Note #2</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 440,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 440,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_ecustom--ConvertibleNotesPayableGross_iI_maCNPDDzvES_zmrA1LQ2ist\" style=\"vertical-align: bottom; background-color: White\"> <td><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\">Total</span></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,235,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,246,000 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--DeferredFinanceCostsNet_iNI_di_msCNPDDzvES_zqHuaHz0Kv31\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Debt discount and issuance costs</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0688\">-</span></td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 84,082 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)</td></tr> <tr id=\"xdx_402_eus-gaap--ConvertibleNotesPayable_iTI_mtCNPDDzvES_zoqatJ1eJSI7\" style=\"vertical-align: bottom; background-color: White\"> <td><span style=\"display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt\">Total convertible notes payable</span></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,235,500 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td style=\"text-align: right\"> 1,161,918 </td><td style=\"text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40A_eus-gaap--ConvertibleNotesPayableCurrent_iI_z4c4D2VchXEe\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Less: current portion</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,235,500 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,161,918 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_405_eus-gaap--ConvertibleLongTermNotesPayable_iI_zrh6Vf5nOtR1\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Non-current portion</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0697\">-</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">$</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"><span style=\"-sec-ix-hidden: xdx2ixbrl0698\">-</span></td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"text-align: justify\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49B_20230101__20231231_zks32IYKAELd\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_49B_20220101__20221231_z3oDzlZuDnrd\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: justify\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Years Ended <br/> December 31,</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"text-align: justify\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> <tr id=\"xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zlR9yMS12E38\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 60%; text-align: justify\">Stock options</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 16%; text-align: right\"> 1,100,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 16%; text-align: right\"> 1,100,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqdqndknoGpc\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: justify; padding-bottom: 1.5pt\">Stock warrants</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,494,854 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 1,576,647 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zw9RhRhh1Ng7\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: justify; padding-bottom: 1.5pt\">Total shares excluded from calculation</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,594,854 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,676,647 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> <tr id=\"xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zBUkEIsvVvz6\" style=\"display: none; vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: justify; padding-bottom: 1.5pt\">Antidilutive securities</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,594,854 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\"> 2,676,647 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"border-bottom: Black 1.5pt solid\">Date Issued</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Number <br/> Outstanding</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Number <br/> Exercisable</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Exercise Price</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: center\">Expiration Date</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 38%\"><span id=\"xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionIssuanceDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--OptionOneMember_z6uu602U658g\" title=\"Date Issued\"> March 12, 2020 </span></td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--OptionOneMember_z7civ8FiQZah\" style=\"width: 10%; text-align: right\" title=\"Number Outstanding\"> 500,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--OptionOneMember_zhCVPYFFg9Bb\" style=\"width: 10%; text-align: right\" title=\"Number Exercisable\"> 500,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--OptionOneMember_z4Bd3i9qkzu2\" style=\"width: 10%; text-align: right\" title=\"Exercise Price\"> 0.40 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 18%; text-align: right\"><span id=\"xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--OptionOneMember_z7O336Jf4MF4\" title=\"Expiration Date\"> March 12, 2025 </span></td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td><span id=\"xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionIssuanceDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zKHBGoRnBBBf\" title=\"Date Issued\"> June 27, 2020 </span></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zZuoM8NumPV4\" style=\"text-align: right\" title=\"Number Outstanding\"> 150,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zO62qCfXfN35\" style=\"text-align: right\" title=\"Number Exercisable\"> 150,000 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zzxxu08MfQ41\" style=\"text-align: right\" title=\"Exercise Price\"> 0.40 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: right\"><span id=\"xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--OptionTwoMember_zhJvJANQff1i\" title=\"Expiration Date\"> June 27, 2025 </span></td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt\"><span id=\"xdx_905_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionIssuanceDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--OptionThreeMember_zOPYuF2Wf0M\" title=\"Date Issued\"> January 1, 2021 </span></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--OptionThreeMember_zPRX529nw8y1\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number Outstanding\"> 450,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--OptionThreeMember_zWULM2PfyQq1\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number Exercisable\"> 450,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt; text-align: left\">$</td><td id=\"xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--OptionThreeMember_zubwZ3ht6Vw3\" style=\"padding-bottom: 1.5pt; text-align: right\" title=\"Exercise Price\"> 0.65 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: right; padding-bottom: 1.5pt\"><span id=\"xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--OptionThreeMember_zf3Q7mUY1U0b\" title=\"Expiration Date\"> December 31, 2025 </span></td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; padding-bottom: 1.5pt\">Total</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left\">\u00a0</td><td id=\"xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--OptionMember_zAM9yGbSOHed\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right\" title=\"Number Outstanding\"> 1,100,000 </td><td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left\">\u00a0</td><td id=\"xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--OptionMember_z4zFFqIs3d51\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right\" title=\"Number Exercisable\"> 1,100,000 </td><td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: right\">\u00a0</td><td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%\"> <tr style=\"vertical-align: bottom\"> <td style=\"border-bottom: Black 1.5pt solid\">Date Issued</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Number <br/> Outstanding</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Number <br/> Exercisable</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; text-align: center\">Exercise Price</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: center\">Expiration Date</td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 38%\"><span id=\"xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuanceDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zxlfZpWMyyU5\" title=\"Date Issued\"> August 10, 2021 </span></td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zztcunf3XSo3\" style=\"width: 10%; text-align: right\" title=\"Number Outstanding\"> 930,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td id=\"xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zTKmasc4A0Ci\" style=\"width: 10%; text-align: right\" title=\"Number Exercisable\"> 930,000 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">$</td><td id=\"xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zvhZBPmVRjZ3\" style=\"width: 10%; text-align: right\" title=\"Exercise Price\"> 1.25 </td><td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 18%; text-align: right\"><span id=\"xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--WarrantOneMember_zxcq1wtJOIag\" title=\"Expiration Date\"> August 9, 2024 </span></td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td><span id=\"xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuanceDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_zfYWEakLK5n1\" title=\"Date Issued\"> February 23, 2022 </span></td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_zTEeaSbDIyoe\" style=\"text-align: right\" title=\"Number Outstanding\"> 14,854 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">\u00a0</td><td id=\"xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_z3hdiNicOyBk\" style=\"text-align: right\" title=\"Number Exercisable\"> 14,854 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: left\">$</td><td id=\"xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_zGUNE7vJIaP9\" style=\"text-align: right\" title=\"Exercise Price\"> 0.705 </td><td style=\"text-align: left\">\u00a0</td><td>\u00a0</td> <td style=\"text-align: right\"><span id=\"xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--WarrantTwoMember_zBipEkhFnGve\" title=\"Expiration Date\"> February 22, 2024 </span></td></tr> <tr style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"padding-bottom: 1.5pt\"><span id=\"xdx_900_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssuanceDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_zfm0RhHqKfAj\" title=\"Date Issued\"> July 19, 2022 </span></td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_zJQWm0ae25mi\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number Outstanding\"> 550,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td id=\"xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_zIhvsVpS7xya\" style=\"border-bottom: Black 1.5pt solid; text-align: right\" title=\"Number Exercisable\"> 550,000 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt; text-align: left\">$</td><td id=\"xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingWeightedAverageExercisePrice_iI_pid_c20231231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_z4p5Z2881JSc\" style=\"padding-bottom: 1.5pt; text-align: right\" title=\"Exercise Price\"> 0.50 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"text-align: right; padding-bottom: 1.5pt\"><span id=\"xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20230101__20231231__us-gaap--AwardTypeAxis__custom--WarrantThreeMember_z8S1yPo4TkJ3\" title=\"Expiration Date\"> July 18, 2025 </span></td></tr> <tr style=\"vertical-align: bottom; background-color: White\"> <td style=\"font-weight: bold; padding-bottom: 1.5pt\">Total</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left\">\u00a0</td><td id=\"xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zXsgUItTJiEi\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right\" title=\"Number Outstanding\"> 1,494,854 </td><td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left\">\u00a0</td><td id=\"xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableNumber_iI_pid_c20231231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zfrK47NtwgY6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right\" title=\"Number Exercisable\"> 1,494,854 </td><td style=\"padding-bottom: 1.5pt; font-weight: bold; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt; text-align: right\">\u00a0</td><td style=\"padding-bottom: 1.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"padding-bottom: 1.5pt\">\u00a0</td></tr> </table>",
        "<table cellpadding=\"0\" cellspacing=\"0\" style=\"font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%\"> <tr style=\"display: none; vertical-align: bottom\"> <td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_495_20230101__20231231_zLB9i4WdLh03\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" id=\"xdx_494_20220101__20221231_zvyZmZcoEjc5\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold\">\u00a0</td> <td colspan=\"6\" style=\"font-weight: bold; text-align: center\">For the Years Ended</td><td style=\"font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"6\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">December 31,</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td style=\"font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2023</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td><td style=\"font-weight: bold; padding-bottom: 1.5pt\">\u00a0</td> <td colspan=\"2\" style=\"border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center\">2022</td><td style=\"padding-bottom: 1.5pt; font-weight: bold\">\u00a0</td></tr> <tr style=\"vertical-align: bottom\"> <td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\">\u00a0</td><td>\u00a0</td><td>\u00a0</td> <td colspan=\"2\">\u00a0</td><td>\u00a0</td></tr> <tr id=\"xdx_40F_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_maCc_z4BIa6JWgTQi\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"width: 64%; text-align: left\">Income tax at federal statutory rate</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 14%; text-align: right\"> 21.00 </td><td style=\"width: 1%; text-align: left\">%</td><td style=\"width: 2%\">\u00a0</td> <td style=\"width: 1%; text-align: left\">\u00a0</td><td style=\"width: 14%; text-align: right\"> 21.00 </td><td style=\"width: 1%; text-align: left\">%</td></tr> <tr id=\"xdx_407_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_maCc_zXprxG4bALvl\" style=\"vertical-align: bottom; background-color: White\"> <td style=\"text-align: left; padding-bottom: 1.5pt\">Valuation allowance</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 21.00 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)%</td><td style=\"padding-bottom: 1.5pt\">\u00a0</td> <td style=\"border-bottom: Black 1.5pt solid; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 1.5pt solid; text-align: right\">( 21.00 </td><td style=\"padding-bottom: 1.5pt; text-align: left\">)%</td></tr> <tr id=\"xdx_40B_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp0_mtCc_zyZMvnBgWKQb\" style=\"vertical-align: bottom; background-color: rgb(204,238,255)\"> <td style=\"text-align: left; padding-bottom: 2.5pt\">Income tax expense</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> \u2014 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td><td style=\"padding-bottom: 2.5pt\">\u00a0</td> <td style=\"border-bottom: Black 2.5pt double; text-align: left\">\u00a0</td><td style=\"border-bottom: Black 2.5pt double; text-align: right\"> \u2014 </td><td style=\"padding-bottom: 2.5pt; text-align: left\">\u00a0</td></tr> </table>"
    ]
}